Download Chapter 90

References
90.1
Chapter 90: Acne
1 Stern S. Dermatologists and office‐based care of dermatologist disease in the 21st
century. J Invest Dermatol Symp Proc 2004;9:126–30.
2 Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp
Dermatol 2005;14:143–52.
3Perkins AC, Cheng CE, Hillebrand GG, et al. Comparison of the epidemiology of
acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol 2011;25:1054–60.
4Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp
Dermatol 2005;14:143–52.
5Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of
the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian
and African American women. J Eur Acad Dermatol Venereol 2011;25:1054–60.
6Thiboutot D, Gollnick H, Bettolli V, et al. New insights into the management of
acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J
Am Acad Dermatol 2009;60(5 Suppl.):S1–50.
7Layton AM, Henderson C, Cunliffe WJ. A clinical evaluation of acne scarring and
its incidence. Clin Exp Dermatol 1994;19:303–8.
8Friedlander SF, Eichenfield LF, Fowler JF Jr, et al. Acne epidemiology and pathophysiology. Semin Cutan Med Surg 2010;29(2 Suppl. 1):2–4.
9Goldberg JL, Dabade TS, Davis SA, et al. Changing age of acne vulgaris visits:
another sign of earlier puberty? Pediatr Dermatol 2011;28:645–8.
10 Kim GK, Michaels BB. Post‐adolescent acne in women: more common and more
clinical considerations. J Drugs Dermatol 2012;11:708–13.
11 Biro FM, Greenspan LC, Galvez MP. Puberty in girls of the 21st century. J Pediatr
Adolesc Gynaecol 2012;25:289–94.
12 Lee Y, Styne D. Influences on the onset and tempo of puberty in human beings
and implications for adolescent psychological development. Horm Behav
2013;64:250–61.
13 Stathakis V, Kilkenny M, Marks R. Descriptive epidemiology of acne vulgaris in
the community. Australas J Dermatol 1997;38:115–23.
14 Wu TQ, Mei SQ, Zhang JX, et al. Prevalence and risk factors of facial acne vulgaris among Chinese adolescents. Int J Adolesc Med Health 2007;19:407–12.
15 Shen Y, Wang T, Zhou C, et al. Prevalence of acne vulgaris in Chinese adolescents
and adults: a community‐based study of 17,345 subjects in six cities. Acta Derm
Venereol 2012;92:40–4.
16 Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in early adolescent boys.
Correlations with pubertal maturation and age. Arch Dermatol 1991;127:210–16.
17 Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris
in young adolescent girls: results of a five‐year longitudinal study. J Pediatr
1997;130:30–9.
18 Mourelatos K, Eady EA, Cunliffe WJ, et al. Temporal changes in sebum excretion
and propionibacterial colonization in preadolescent children with and without
acne. Br J Dermatol 2007;156:22–31.
19 Ibanez L, Dimartino‐Nardi J, Potau N, et al. Premature adrenarche: normal variant or forerunner of adult disease? Endocr Rev 2000;21:671–96.
20 Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first‐degree relatives of affected and unaffected individuals. Br
J Dermatol 1999;141:297–300.
21 Khunger N, Kumar C. A clinico‐epidemiological study of adult acne: is it different from adolescent acne? Indian J Dermatol Venereol Leprol 2012;78:335–41.
22 Perkins AC, Maglione J, Hillebrand GG, et al. Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt) 2012;21:223–30.
23 Silverberg JI, Silverberg NB. Epidemiology and extracutaneous comorbidities of severe acne in adolescence: a U.S. population‐based study. Br J Dermatol
2014;170:1136–42.
24 Rombouts S, Nijsten T, Lambert J. Cigarette smoking and acne in adolescents:
results from a cross‐sectional study. J Eur Acad Dermatol Venereol 2007;21:326–33.
25 Uslu G, Sendur N, Uslu M, et al. Acne: prevalence, perceptions and effects on
psychological health among adolescents in Aydin, Turkey. J Eur Acad Dermatol
Venereol 2008;22:462–9.
c90_ref.indd 1
26 Hanisah A, Omar K, Shah SA. Prevalence of acne and its impact on the quality of
life in school‐aged adolescents in Malaysia. J Prim Health Care 2009;1:20–5.
27 Muthupalaniappen L, Tan HC, Puah JW, et al. Acne prevalence, severity and risk
factors among medical students in Malaysia. Clin Ter 2014;165:187–92.
28 Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010:
an analysis of the prevalence and impact of skin conditions. J Invest Dermatol
2014;134:1527–34.
29 Davis SA, Narahari S, Feldman SR, et al. Top dermatologic conditions in
patients of color: an analysis of nationally representative data. J Drugs Dermatol
2012;11:466–73.
30 Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am
2009;93:1161–81.
31 Chen W, Obermayer‐Pietsch B, Hong JB, et al. Acne‐associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol
2011;25:637–46.
32 Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin
Endocrinol Metab 2013;98:4565–92.
33 Wijeyaratne CN, Balen AH, Barth JH, et al. Clinical manifestations and insulin
resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and
Caucasians: is there a difference? Clin Endocrinol 2002;57:343–50.
34 Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women:
experience with over 1000 consecutive patients. J Clin Endocrinol Metab
2004;89:453–62.
35 Chang WY, Knochenhauer ES, Bartolucci AA, et al. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three
major clinical subgroups. Fertil Steril 2005;83:1717–23.
36 Hahn S, Bering van Halteren W, Roesler S, et al. The combination of increased
ovarian volume and follicle number is associated with more severe hyperandrogenism in German women with polycystic ovary syndrome. Exp Clin Endocrinol
Diabetes 2006;114:175–81.
37 Li L, Yang D, Chen X, et al. Clinical and metabolic features of polycystic ovary
syndrome. Int J Gynaecol Obstet 2007;97:129–34.
38 Liou TH, Yang JH, Hsieh CH, et al. Clinical and biochemical presentations of
polycystic ovary syndrome among obese and nonobese women. Fertil Steril
2009;92:1960–5.
39 Pembe AB, Abeid MS. Polycystic ovaries and associated clinical and biochemical
features among women with infertility in a tertiary hospital in Tanzania. Tanzania J Health Res 2009;11:175–80.
40 Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in
relationship with hyperandrogenemia in obese adolescent girls with polycystic
ovary syndrome. Eur J Endocrinol 2010;162:1093–9.
41 Bekx MT, Connor EC, Allen DB. Characteristics of adolescents presenting to
a multidisciplinary clinic for polycystic ovarian syndrome. J Pediatr Adolesc
Gynecol 2010;23:7–10.
42 Bhattacharya SM, Ghosh M. Insulin resistance and adolescent girls with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010;23:158–61.
43 Bhattacharya SM, Ghosh M, Nandi N. Effects of drospirenone pill in Indian
women with polycystic ovary syndrome. J Turk Ger Gynecol Assoc 2011;12:144–7.
44 Bhattacharya SM, Ghosh M, Basu R. Effects of ethinyl estradiol and desogestrel
on clinical and metabolic parameters in Indian patients with polycystic ovary
syndrome. J Obstet Gynaecol Res 2012;38:285–90.
45 Siddiqui IA, Tamimi W, Tamim H, et al. A study on clinical and sonographic
features in obese and nonobese patients with polycystic ovary syndrome. Arch
Gynecol Obstet 2010;281:467–71.
46 Ozdemir S, Ozdemir M, Gorkemli H, et al. Specific dermatologic features of
the polycystic ovary syndrome and its association with biochemical markers
of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand
2010;89:199–204.
47 Asgharnia M, Mirblook F, Ahmad Soltani M. The Prevalence of Polycystic Ovary
Syndrome (PCOS) in High School Students in Rasht in 2009 According to NIH
Criteria. Int J Fertil Steril 2011;4:156–9.
11 March 2016 7:24 PM
90.2
Chapter 90: Acne
48 Bronstein J, Tawdekar S, Liu Y, et al. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol
2011;24:15–20.
49 Chen MJ, Chen CD, Yang JH, et al. High serum dehydroepiandrosterone sulfate
is associated with phenotypic acne and a reduced risk of abdominal obesity in
women with polycystic ovary syndrome. Hum Reprod 2011;26:227–34.
50 Skampardonis N, Kouskoukis A, Karpouzis A, et al. Marked hyperandrogenemia and acne associated with polycystic ovaries in Greek women with polycystic
ovary syndrome. Clin Exp Obstet Gynecol 2011;38:168–71.
51 Baldani DP, Skrgatic L, Goldstajn MS, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol
2012;36:1413–18.
52 Nair MK, Pappachan P, Balakrishnan S, et al. Menstrual irregularity and poly
cystic ovarian syndrome among adolescent girls – a 2 year follow‐up study.
Indian J Pediatr 2012;79 Suppl. 1:S69–73.
53 Saxena P, Prakash A, Nigam A, et al. Polycystic ovary syndrome: Is obesity a
sine qua non? A clinical, hormonal, and metabolic assessment in relation to body
mass index. Indian J Endocrinol Metabol 2012;16:996–9.
54 Hacivelioglu S, Gungor AN, Gencer M, et al. Acne severity and the Global
Acne Grading System in polycystic ovary syndrome. Int J Gynaecol Obstet
2013;123:33–6.
55 McManus SS, Levitsky LL, Misra M. Polycystic ovary syndrome: clinical presentation in normal‐weight compared with overweight adolescents. Endocr Pract
2013;19:471–8.
56 Musmar S, Afaneh A, Mo’alla H. Epidemiology of polycystic ovary syndrome: a
cross sectional study of university students at An‐Najah national university‐Palestine. Reprod Biol Endocrinol 2013;11:47.
57 Wang ET, Kao CN, Shinkai K, et al. Phenotypic comparison of Caucasian and
Asian women with polycystic ovary syndrome: a cross‐sectional study. Fertil
Steril 2013;100:214–18.
58 Hong JS, Kwon HH, Park SY, et al. Cutaneous manifestations of the subtypes of
polycystic ovary syndrome in Korean patients. J Eur Acad Dermatol Venereol 2014:
Mar 14 epub.
59 Quinn M, Shinkai K, Pasch L, et al. Prevalence of androgenic alopecia in patients
with polycystic ovary syndrome and characterization of associated clinical and
biochemical features. Fertil Steril 2014;101:1129–34.
60 Tuten A, Sahmay S, Oncul M, et al. Serum AMH levels in the differential
diagnosis of hyperandrogenemic conditions. Eur J Obstet Gynecol Reprod Biol
2014;177:121–5.
61 Williamson K, Gunn AJ, Johnson N, et al. The impact of ethnicity on the presentation of polycystic ovarian syndrome. Aust NZ J Obstet Gynaecol 2001;41:202–6.
62 Christensen SB, Black MH, Smith N, et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril 2013;100:470–7.
63 Anderson AD, Solorzano CM, McCartney CR. Childhood obesity and its impact
on the development of adolescent PCOS. Semin Reprod Med 2014;32:202–13.
64 Williams RM, Ong KK, Dunger DB. Polycystic ovarian syndrome during puberty
and adolescence. Mol Cell Endocrinol 2013;373:61–7.
65 Vilmann LS, Thisted E, Baker JL, et al. Development of obesity and polycystic
ovary syndrome in adolescents. Horm Res Paediatr 2012;78:269–78.
66 Diamanti‐Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol
2010;24:173–83.
67 Musmar S, Afaneh A, Mo’alla H. Epidemiology of polycystic ovary syndrome:
a cross sectional study of university students at An‐Najah National University,
Palestine. Reprod Biol Endocrinol 2013;11:47.
68 Nair MK, Pappachan P, Balakrishnan S, et al. Menstrual irregularity and polycystic ovarian syndrome among adolescent girls: a 2 year follow‐up study. Indian J
Pediatr 2012;79(Suppl. 1):S69–73.
69 Esmaeilzadeh S, Delavar MA, Amiri M, et al. Polycystic ovary syndrome in Iranian adolescents. Int J Adolesc Med Health 2014;26:559–65.
70 Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic
ovaries. Br J Dermatol 1989;121:675–80.
71 Maluki AH. The frequency of polycystic ovary syndrome in females with resistant acne vulgaris. J Cosmet Dermatol 2010;9:142–8.
72 Witchel SF, Azziz R. Nonclassic congenital adrenal hyperplasia. Int J Pediatr
Endocrinol 2010:625105 doi: 10.1155/2010/625105.
73 Honour JW. 17‐Hydroxyprogesterone in children, adolescents and adults. Ann
Clin Biochem 2014;51:424–40.
c90_ref.indd 2
74Ostlere LS, Rumsby G, Holownia P, et al. Carrier status for steroid 21‐hydroxylase deficiency is only one factor in the variable phenotype of acne. Endocrinology 1998;48:209–15.
75Marynick S Chakmakjian Z, McCaffree D, et al. Androgen excess in cystic acne.
N Engl J Med 1983;308:981–6.
76Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005;365:2125–
36.
77New MI. Extensive clinical experience: non classical 21‐hydroxylase deficiency.
J Clin Endocrinol Metab 2006;91:4205–14.
78Degitz K, Plackzek M, Arnold B, et al. Congenital adrenal hyperplasia and acne
in male patients. Br J Dermatol 2003;148:1263–6.
79Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004;22:419–
28.
80Chalmers RJ, Ead RD, Beck MH, Dewis P, Anderson DC. Acne vulgaris and
hidradenitis suppurativa are presenting features of acromegaly. BMJ (Clin Res
Ed) 1983;287:1346–7.
81Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000;21:363–92.
82Deplewski D, Rosenfield RL. Growth hormone and insulin‐like growth factors
have different effects on sebaceous cell growth and differentiation. Endocrinology 1999;149:4089–94.
83Rizvi AA. Some clues and pitfalls in the diagnosis of acromegaly. Endocr Pract
2004;10:348–52.
84Beretta‐Piccoli BC, Sauvain MHJ, Gal I, et al. Synovitis, acne pustulosis, hyperostosis osteitis (SAPHO) syndrome in childhood: a report of 10 cases and
review of the literature. Eur J Pediatr 2000;159:594–601.
85Van Doorman S, Barraclough D, McColl G, et al. SAPHO: rare or just not recognised? Semin Arthritis Rheum 2000;93:70–7.
86Colina M, Lo Monaro A, Khodien M. Propionibacterium acnes and SAPHO: a
case report and a literature review. Clin Exp Rheumatol 2007;25:457–60.
87Olivieri I, Padula A, Palazzi C. Pharmacological management of SAPHO syndrome. Exp Opin Invest Drugs 2006;15:1229–33.
88Delattre E, Guillot X, Godfrin‐Valnet M, et al. SAPHO syndrome treatment with
intravenous pamidronate: retrospective study of 22 patients. Joint Bone Spine
2014;81:456–8.
89Iqbal M, Kolodney MS. Acne fulminans and synovitis‐acne‐pustulosis‐hyperostosis‐osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol
2005;52(5 Suppl. 1):S118–20.
90Firinu D, Murgia G, Lorrai MM, et al. Biological treatments for SAPHO syndrome: an update. Inflamm Allergy Drug Targets 2014;13:199–205.
91Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti‐TNF‐alpha therapy may induce persistent amelioration of osteoarticular complaints, but exacerbate cutaneous manifestations. Rheumatology 2006;45:730–3.
92Rager KM, Omar HA. Androgen excess disorders in women: the severe insulin‐
resistant hyperandrogen syndrome, HAIR‐AN. Sci World J 2006;6:116–21.
93Elmer KB, George RM. HAIR‐AN syndrome: a multisystem challenge. Am Fam
Physician 2001;63:2385–90.
94Shen Z, Hao F, Wei P. HAIR‐AN syndrome in a male adolescent with concomitant vitiligo. Arch Dermatol 2009;145:492–4.
95Ingletto D, Ruggiero L, De Sanctis V. HAIR‐AN syndrome (hyperandrogenism, insulin resistance, acanthosis nigricans) in an adolescent with Cohen’s
syndrome. Minerva Pediatr 2001;53:493–4.
96Somani N, Harrison S, Bergfeld WF. The clinical evaluation of hirsutism. Dermatol Ther 2008;21:376–91.
97Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of insulin receptor (type A and Rabson–Mendehall syndromes): a 30‐year prospective.
Medicine (Baltimore) 2004;83:209–22.
98Makrantonaki E, Vogel K, Fimmel S, et al. Interplay of IGF‐1 and 17beta‐estradiol at age‐specific levels in human sebocytes and fibroblasts in vitro. Exp Gerontol 2008;43:939–46.
99Orfanos CE. Antiandrogenos en dermatologia. Arch Arg Derm 1982;32(Suppl.
1):51–5.
100 Orfanos CE, Adler YA, Zouboulis CC. The SAHA syndrome. Horm Res
2000;54:251–8.
101 Yang H, Reinherz E. CD2BP1 modulates CD2‐dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)‐PEST. J Immunol 2006;176:5898–907.
102 Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP/CD2BP1
protein, defining Mediterranean fever and PAPA syndrome as disorders in the
same pathway. Proc Natl Acad Sci USA 2003;100:13501–6.
11 March 2016 7:24 PM
References
103 Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum and acne: PAPA syndrome. Rheumatology (Oxford) 2005;44:406–8.
104 Demodowich AP, Freeman AF, Kuhns DB, et al. Genotype, phenotype and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gandrenosum, and acne). Arthritis Rheum 2012;64:2022–7.
105 Apert E. De l’a acroencephalosyndactylie. Bull Soc Med Hop (Paris) 1906;23:1310–
30.
106 Boulet SL, Rasmussen SA, Honein MA. A population‐based study of craniosynostosis in metropolitan Atlanta, 1989–2003. Am J Med Genet A 2008;146:984–91.
107 Kreiborg S, Cohen MM Jr. The oral manifestations of Apert’s syndrome. J
Cranofac Genet Dev Biol 1992;12:41–8.
108 Freiman A, Tessler O, Barankin B. Apert syndrome. Int J Dermatol
2006;45:1341–3.
109 Atherton DJ, Rebella T. Apert’s syndrome with severe acne vulgaris. Proc R Soc
Med 1976;69:517–18.
110 Cohn MS, Mahon MJ. Apert’s syndrome in a patient with hyperhidrosis. Cutis
1993;52:205–8.
111 Solomon LM, Fretzin D, Pruzansky S. Pilosebaceous abnormalities in Apert’s
syndrome. Arch Dermatol 1970;102:381–5.
112 Henderson CA, Knaggs H, Clark A, et al. Apert’s syndrome and androgen receptor staining of the basal cells of sebaceous glands. Br J Dermatol 1995;132:139–43.
113 Campanati A, Marconi B, Penna L, et al. Pronounced and early acne in Apert’s
syndrome: a case successfully treated with oral isotretinoin. Eur J Dermatol
2002;12:496–8.
114 Gilaberte M, Puig L, Alomar A. Isotretinoin treatment of acne in a patient with
Apert’s syndrome. Pediatr Dermatol 2003;20:443–6.
115 Cohen MM, Kreiborg S. Cutaneous manifestations of Apert’s syndrome. Am J
Med Genet 1995;58:94–6.
116 Melnik BC. Role of FGFR2 signaling in the pathogenesis of acne. Dermatoendocrinology 2009;1:141–56.
117 Downs AMR, Condon CA, Tan R. Isotretinoin therapy for antibiotic‐refractory
acne in Apert’s syndrome. Clin Exp Dermatol 1999;24:461–3.
118 Cuerda E, Del Pozo J, Rodriguez‐Lozano J, et al. Acne in Apert’s syndrome:
treatment with isotretinoin. J Dermatol Treat 2003;14:43–5.
119 Steffen C. The acneiform eruption of Apert’s syndrome is not acne vulgaris. Am
J Dermatopathol 1984;6:213–20.
120 Momin SB, Peterson A, Del Rosso JQ. A status report on drug‐associated acne
and acneiform eruptions. J Drugs Dermatol 2010;9:627–36.
121 Du‐Thanh A, Kluger N, Bensalleh H, et al. Drug‐induced acneiform eruption.
Am J Clin Dermatol 2011;12:233–45.
122 Dessinioti C, Antoniou C, Katsambas A. Acneiform eruptions. Clin Dermatol
2014;32:24–34.
123 Plewig G, Kligman AM. Induction of acne by topical steroids. Arch Dermatol
Forsch 1973;247:29–52.
124 Monk B, Cunliffe WJ, Layton AM, Rhodes DJ. Acne induced by inhaled corticosteroids. Clin Exp Dermatol 1993;18:148–50.
125 Daltrey DC, Cunliffe WJ. Effect of betamethasone valerate on the normal facial
skin flora. Acta Derm Venereol (Stockh) 1983;63:160–2.
126 Bong JL, Connell JM, Lever R. Intranasal betamethasone induced acne and
adrenal suppression. Br J Dermatol 2000;142:579–80.
127 Fung MA, Berger TG. A prospective study of acute‐onset steroid acne associated
with administration of intravenous corticosteroids. Dermatology 2000;200:43–4.
128 Guillot B. Adverse skin reactions to inhaled steroids. Expert Opin Drug Saf
2002;1:325–9.
129 Plewig G, Strzeminski YA. Iodide and skin disease. Dtsch Med Wochenschr
1985;110:1266–9.
130 Razavi Z, Moeini B, Shafiei Y, et al. Prevalence of anabolic steroid use and associated factors among body‐builders in Hamadan, West Province of Iran. J Res
Health Sci 2014;14:163–6.
131 Kiraly CL, Alen M, Korvola J, et al. The effect of testosterone and anabolic steroids on the skin surface lipids and the population of Propionibacterium acnes
in young post‐pubertal men. Acta Derm Venereol 1988;68:21–6.
132 Scott MJ, Scott AM. Effects of anabolic‐androgenic steroids on the pilosebaceous unit. Cutis 1992;50:113–16.
133 O’Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic‐androgenic steroids: medical assessment of present, past and potential users. Med J Aust 2000;173:323–7.
c90_ref.indd 3
90.3
134 Mahé E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic and
pathogenic aspects. J Am Acad Dermatol 2006;55:139–42.
135 Kunzle N, Vebetz JP, Pascual M, et al. Sirolimus‐induced acneifom eruption.
Dermatology 2005;211:366–9.
136 Moloney FJ, Kene S, O’Kelly P, et al. The impact of skin disease following renal
transplantation on quality of life. Br J Dermatol 2005;153:574–8.
137 Bakos L, Marchiori BR. Focal acne during topical tacrolimus therapy for vitiligo. Arch Dermatol 2007;143:1223–4.
138 Oztas P, Aksakal AB, Oztas MO, et al. Severe acne with lithium. Ann Pharmacother 2001;35:961–2.
139 Scarfi F, Arunachalam M. Lithium acne. Can Med Assoc J 2013;185:1525.
140 Vexiau P, Husson C, Chivot M, et al. Androgen excess in women with acne
alone compared with women with acne and/or hirsutism. J Invest Dermatol
1990;94:279–83.
141 Bettoli V, Trimurti S, Lombardi AR, et al. Acne due to amineptine abuse. J Eur
Acad Dermatol Venereol 1998;10:281–3.
142 Aithal V, Appaih P. Lithium induced hidradenitis suppurativa and acne conglobata. Indian J Dermatol Venereol Leprol 2004;70:307–9.
143 Yeung CK, Chan HH, Cutaneous adverse effects of lithium: epidemiology and
management. Am J Dermatol 2004;5:3–8.
144 Cohen EB, Rossen NN. Acne vulgaris in connection with the use of progestogens in a hormonal IUD or a subcutaneous implant. Ned Tijdschr Geneeskd
2003;147:2137–9.
145 Cohen LK, George W, Smith R. Isoniazid‐induced acne and pellagra: occurrence in slow inactivators of isoniazid. Arch Dermatol 1974;109:377–81.
146 Greenwood R, Fenwick PB, Cunliffe WJ. Acne and anti‐convulsants. BMJ
1983;287:1669–70.
147 Papa CM. Acne and hidden iodides [Letter]. Arch Dermatol 1976;112:555–6.
148 Dupre A, Alberel N, Bonafe JL, et al. Vitamin B‐12 induced acnes. Cutis
1979;24:210–11.
149 Kang D, Baochen Shi, Erfe MC, et al. Vitamin B12 modulates the transcriptome
of the skin microbiota in acne pathogenesis. Sci Transl Med 2015;7(293):293ra103.
150 Busam KJ, Capodiece P, Motzer R, et al. Cutaneous side‐effects in cancer
patients treated with the anti epidermal growth factor receptor antibody C 225.
Br J Dermatol 2001;144:1169–76.
151 Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in
cancer patients receiving epidermal growth factor receptor targeted therapies. J
Dtsch Dermatol Ges 2005;3:599–606.
152 Molinari E, De Quatrebarbes J, Anbdre T, et al. Cetuximab induced acne. Dermatology 2005;211:330–3.
153 Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin
of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol
2005;153:849–51.
154 Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol
2013;168:474–85.
155 Xu SX, Wang HL, Fan X, et al. The familial risk of acne vulgaris in Chinese Hans:
a case‐control study. J Eur Acad Dermatol Venereol 2007;21:602–5.
156 Wei B, Pang Y, Zhu H, et al. The epidemiology of adolescent acne in North East
China. J Eur Acad Dermatol Venereol 2010;24:953–7.
157 Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index,
selected dietary factors, menstrual history, and risk of moderate to severe acne
in adolescents and young adults. J Am Acad Dermatol 2012;67:1129–35.
158 Goulden V, McGeown CH, Cunliffe WJ. The familial risk of adult acne: a comparison between first‐degree relatives of affected and unaffected individuals.
Br J Dermatol 1999;141:297–300.
159 Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community‐based study. J Invest Dermatol
2009;129:2136–41.
160 Ismail NH, Manaf ZA, Azizan NZ. High glycemic load diet, milk and ice cream
consumption are related to acne vulgaris in Malaysian young adults: a case
control study. BMC Dermatol 2012;12:13.
161 Karciauskiene J, Valiukeviciene S, Gollnick H, et al. The prevalence and risk
factors of adolescent acne among schoolchildren in Lithuania: a cross‐sectional
study. J Eur Acad Dermatol Venereol 2014;28:733–40.
162 Suh DH, Kim BY, Min SU, et al. A multicenter epidemiological study of acne
vulgaris in Korea. Int J Dermatol 2011;50:673–81.
163 Cho EB, Ha JM, Park EJ, et al. Heredity of acne in Korean patients. J Dermatol
2014;41:915–17.
11 March 2016 7:24 PM
90.4
Chapter 90: Acne
164 Ballanger F, Baudry P, N’Guyen JM, et al. Heredity: a prognostic factor for acne.
Dermatology 2006;212:145–9.
165 Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne:
a twin study. Br J Dermatol 1988;118:393–6.
166 Navarini AA, Simpson MA, Weale M, et al. Genome‐wide association study
identifies three novel loci for severe acne vulgaris. Nat Commun 2014;5:4020.
167 Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western
civilization. Arch Dermatol 2002;138:1584–90.
168 Schaefer O. When the Eskimo comes to town. Nutr Today 1971;6:8–16.
169 Tan HH, Tan AW, Barkham T, et al. Community‐based study of acne vulgaris in
adolescents in Singapore. Br J Dermatol 2007;157:547–51.
170 Rigopoulos D, Gregoriou S, Ifandi A, et al. Coping with acne: beliefs and perceptions in a sample of secondary school Greek pupils. J Eur Acad Dermatol
Venereol 2007;21:806–10.
171 Yahya H. Acne vulgaris in Nigerian adolescents: prevalence, severity, beliefs,
perceptions, and practices. Int J Dermatol 2009;48:498–505.
172 Jung JY, Yoon MY, Min SU, et al. The influence of dietary patterns on acne vulgaris in Koreans. Eur J Dermatol 2010;20:768–72.
173 El‐Akawi Z, Abdel‐Latif Nemr N, Abdul‐Razzak K, et al. Factors believed by
Jordanian acne patients to affect their acne condition. Eastern Med Health J
2006;12:840–6.
174 Poli F, Auffret N, Beylot C, et al. Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol 2011;91:531–6.
175 Burris J, Rietkerk W, Woolf K. Relationships of self‐reported dietary factors and
perceived acne severity in a cohort of New York young adults. J Acad Nutr Diet
2014;114:384–92.
176 Aksu AE, Metintas S, Saracoglu ZN, et al. Acne: prevalence and relationship with dietary habits in Eskisehir, Turkey. J Eur Acad Dermatol Venereol
2012;26:1503–9.
177 Veith WB, Silverberg NB. The association of acne vulgaris with diet. Cutis
2011;88:84–91.
178 Smith RN, Mann NJ, Braue A, et al. The effect of a high‐protein, low glycemic‐load diet versus a conventional, high glycemic‐load diet on biochemical
parameters associated with acne vulgaris: a randomized, investigator‐masked,
controlled trial. J Am Acad Dermatol 2007;57:247–56.
179 Smith RN, Braue A, Varigos GA, et al. The effect of a low glycemic load diet
on acne vulgaris and the fatty acid composition of skin surface triglycerides. J
Dermatol Sci 2008;50:41–52.
180 Kaymak Y, Adisen E, Ilter N, et al. Dietary glycemic index and glucose, insulin,
insulin‐like growth factor‐I, insulin‐like growth factor binding protein 3, and
leptin levels in patients with acne. J Am Acad Dermatol 2007;57:819–23.
181 Smith R, Mann N, Makelainen H, et al. A pilot study to determine the short‐
term effects of a low glycemic load diet on hormonal markers of acne: a nonrandomized, parallel, controlled feeding trial. Mol Nutr Food Res 2008;52:718–26.
182 Adebamowo CA, Spiegelman D, Danby FW, et al. High school dietary dairy
intake and teenage acne. J Am Acad Dermatol 2005;52:207–14.
183 Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne
in adolescent girls. Dermatol Online J 2006;12:1.
184 Adebamowo CA, Spiegelman D, Berkey CS, et al. Milk consumption and acne
in teenaged boys. J Am Acad Dermatol 2008;58:787–93.
185 Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community‐based study. J Invest Dermatol
2009;129:2136–41.
186 Halvorsen JA, Dalgard F, Thoresen M, et al. Is the association between acne
and mental distress influenced by diet? Results from a cross‐sectional population study among 3775 late adolescents in Oslo, Norway. BMC Public Health
2009;9:340.
187 Jung JY, Yoon MY, Min SU, et al. The influence of dietary patterns on acne vulgaris in Koreans. Eur J Dermatol 2010;20:768–72.
188 Reynolds RC, Lee S, Choi JY, et al. Effect of the glycemic index of carbohydrates
on Acne vulgaris. Nutrients 2010;2:1060–72.
189 Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index,
selected dietary factors, menstrual history, and risk of moderate to severe acne
in adolescents and young adults. J Am Acad Dermatol 2012;67:1129–35.
190 Ismail NH, Manaf ZA, Azizan NZ. High glycemic load diet, milk and ice cream
consumption are related to acne vulgaris in Malaysian young adults: a case
control study. BMC Dermatol 2012;12:13.
c90_ref.indd 4
191 Kwon HH, Yoon JY, Hong JS, et al. Clinical and histological effect of a low
glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. Acta Derm Venereol 2012;92:241–6.
192 Skroza N, Tolino E, Semyonov L, et al. Mediterranean diet and familial dysmetabolism as factors influencing the development of acne. Scand J Public Health
2012;40:466–74.
193 Burris J, Rietkerk W, Woolf K. Relationships of self‐reported dietary factors
and perceived acne severity in a cohort of New York young adults. J Acad Nutr
Dietet 2014;114:384–92.
194 Block SG, Valins WE, Caperton CV, et al. Exacerbation of facial acne vulgaris
after consuming pure chocolate. J Am Acad Dermatol 2011;65:e114–15.
195 Caperton C, Block S, Viera M, et al. Double‐blind, placebo‐controlled study
assessing the effect of chocolate consumption in subjects with a history of acne
vulgaris. J Clin Aesthet Dermatol 2014;7:19–23.
196 Smith RN, Mann NJ, Braue A, et al. The effect of a high‐protein, low glycemic‐load diet versus a conventional, high glycemic‐load diet on biochemical
parameters associated with acne vulgaris: a randomized, investigator‐masked,
controlled trial. J Am Acad Dermatol 2007;57:247–56.
197 Kwon HH, Yoon JY, Hong JS, et al. Clinical and histological effect of a low
glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. Acta Derm Venereol 2012;92:241–6.
198 Kaymak Y, Adisen E, Ilter N, et al. Dietary glycemic index and glucose, insulin,
insulin‐like growth factor‐I, insulin‐like growth factor binding protein 3, and
leptin levels in patients with acne. J Am Acad Dermatol 2007;57:819–23.
199 Reynolds RC, Lee S, Choi JY, et al. Effect of the glycemic index of carbohydrates
on acne vulgaris. Nutrients 2010;2:1060–72.
200 Smith R, Mann N, Makelainen H, et al. A pilot study to determine the short‐
term effects of a low glycemic load diet on hormonal markers of acne: a nonrandomized, parallel, controlled feeding trial. Mol Nutr Food Res 2008;52:718–26.
201 Bowe W, Patel NB, Logan AC. Acne vulgaris, probiotics and the gut–brain–skin
axis: from anecdote to translational medicine. Benef Microbes 2014;5:185–99.
202 Melnik B. Dietary intervention in acne: attenuation of increased mTORC1 signaling promoted by Western diet. Dermatoendocrinology 2012;4:20–32.
203 Khayef G, Young J, Burns‐Whitmore B, et al. Effects of fish oil supplementation
on inflammatory acne. Lipids Health Dis 2012;11:165.
204 Skroza N, Tolino E, Semyonov L, et al. Mediterranean diet and familial dysmetabolism as factors influencing the development of acne. Scand J Public Health
2012;40:466–74.
205 Muizzuddin N, Maher W, Sullivan M, et al. Physiological effect of a probiotic on
skin. J Cosmetic Sci 2012;63:385–95.
206 Roudsari MR, Karimi R, Mortazavian AM. Health effects of probiotics on the
skin. Crit Rev Food Sci Nutr 2015;55:1219–40.
207 Baquerizo Nole KL, Yim E, Keri JE. Probiotics and prebiotics in dermatology. J
Am Acad Dermatol 2014;71:814–21.
208 Jung JY, Kwon HH, Hong JS, et al. Effect of dietary supplementation with
omega‐3 fatty acid and gamma‐linolenic acid on acne vulgaris: a randomised,
double‐blind, controlled trial. Acta Derm Venereol 2014;94:521–5.
209 Di Landro A, Cazzaniga S, Parazzini F, et al. Family history, body mass index,
selected dietary factors, menstrual history, and risk of moderate to severe acne
in adolescents and young adults. J Am Acad Dermatol 2012;67:1129–35.
210 Tsai MC, Chen W, Cheng YW, et al. Higher body mass index is a significant risk
factor for acne formation in schoolchildren. Eur J Dermatol 2006;16:251–3.
211 Hogewoning AA, Koelemij I, Amoah AS, et al. Prevalence and risk factors of
inflammatory acne vulgaris in rural and urban Ghanaian schoolchildren. Br J
Dermatol 2009;161:475–7.
212 Karciauskiene J, Valiukeviciene S, Gollnick H, et al. The prevalence and risk
factors of adolescent acne among schoolchildren in Lithuania: a cross‐sectional
study. J Eur Acad Dermatol Venereol 2014;28:733–40.
213 Halvorsen JA, Vleugels RA, Bjertness E, et al. A population‐based study of acne
and body mass index in adolescents. Arch Dermatol 2012;148:131–2.
214 Del Prete M, Mauriello MC, Faggiano A, et al. Insulin resistance and acne: a new
risk factor for men? Endocrine 2012;42:555–60.
215 Ismail NH, Manaf ZA, Azizan NZ. High glycemic load diet, milk and ice cream
consumption are related to acne vulgaris in Malaysian young adults: a case
control study. BMC Dermatol 2012;12:13.
216 Alan S, Cenesizoglu E. Effects of hyperandrogenism and high body mass index
on acne severity in women. Saudi Med J 2014;35:886–9.
11 March 2016 7:24 PM
References
217 Yang JH, Weng SL, Lee CY, et al. A comparative study of cutaneous manifestations of hyperandrogenism in obese and non‐obese Taiwanese women. Arch
Gynecol Obstet 2010;282:327–33.
218 Liou TH, Yang JH, Hsieh CH, et al. Clinical and biochemical presentations of
polycystic ovary syndrome among obese and nonobese women. Fertil Steril
2009;92:1960–5.
219 Chen MJ, Chen CD, Yang JH, et al. High serum dehydroepiandrosterone sulfate
is associated with phenotypic acne and a reduced risk of abdominal obesity in
women with polycystic ovary syndrome. Hum Reprod 2011;26:227–34.
220 Baldani DP, Skrgatic L, Goldstajn MS, et al. Clinical, hormonal and metabolic
characteristics of polycystic ovary syndrome among obese and non‐obese
women in the Croatian population. Coll Antropol 2013;37:465–70.
221 Hacivelioglu S, Gungor AN, Gencer M, et al. Acne severity and the Global
Acne Grading System in polycystic ovary syndrome. Int J Gynaecol Obstet
2013;123:33–6.
222 Tamimi W, Siddiqui IA, Tamim H, et al. Effect of body mass index on clinical
manifestations in patients with polycystic ovary syndrome. Int J Gynaecol Obstet
2009;107:54–7.
223 Ibricevic D, Asimi ZV. Frequency of prediabetes in women with polycystic
ovary syndrome. Med Arch 2013;67:282–5.
224 McManus SS, Levitsky LL, Misra M. Polycystic ovary syndrome: clinical presentation in normal‐weight compared with overweight adolescents. Endocr
Pract 2013;19:471–8.
225 Saxena P, Prakash A, Nigam A, et al. Polycystic ovary syndrome: Is obesity a
sine qua non? A clinical, hormonal, and metabolic assessment in relation to
body mass index. Indian J Endocrinol Metabol 2012;16:996–9.
226 Shabir I, Ganie MA, Praveen EP, et al. Morning plasma cortisol is low among obese
women with polycystic ovary syndrome. Gynecol Endocrinol 2013;29:1045–7.
227 Kurzen H, Wessler I, Kirkpatrick CJ, et al. The non‐neuronal cholinergic system
of human skin. Horm Metab Res 2007;39:125–35.
228 Hakonsen LB, Olsen J, Stovring H, et al. Maternal cigarette smoking during
pregnancy and pubertal development in sons. A follow‐up study of a birth
cohort. Andrology 2013;1:348–55.
229 Galobardes B, Davey Smith G, Jeffreys M, et al. Acne in adolescence and cause‐
specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am J Epidemiol 2005;161:1094–101.
230 Frisch RE. Weight at menarche: similarity for well‐nourished and under‐nourished girls at differing ages, and evidence for histologic constancy. Pediatrics
1972;50:445–50.
231 Lucky AW. Quantitative documentation of a premenstrual flare of facial acne in
adult women. Arch Dermatol 2004;140:423–4.
232 Fisher DA. Desideratum dermatologicum–cause and control of premenstrual
acne flare. Int J Dermatol 2000;39:334–6.
233 Stoll S, Shalita AR, Webster GF, et al. The effect of the menstrual cycle on acne. J
Am Acad Dermatol 2001;45:957–60.
234 Poli F, Auffret N, Beylot C, et al. Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol 2011;91:531–6.
235 Al‐Ameer AM, Al‐Akloby OM. Demographic features and seasonal variations
in patients with acne vulgaris in Saudi Arabia: a hospital‐based study. Int J Dermatol 2002;41:870–1.
236 El‐Akawi Z, Abdel‐Latif Nemr N, Abdul‐Razzak K, et al. Factors believed by
Jordanian acne patients to affect their acne condition. Eastern Med Health J
2006;12:840–6.
237 Adityan B, Thappa DM. Profile of acne vulgaris – a hospital‐based study from
South India. Indian J Dermatol Venereol Leprol 2009;75:272–8.
238 Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community‐based study. J Invest Dermatol
2009;129:2136–41.
239 Jung JY, Yoon MY, Min SU, et al. The influence of dietary patterns on acne vulgaris in Koreans. Eur J Dermatol 2010;20:768–72.
240 Poli F, Auffret N, Beylot C, et al. Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol 2011;91:531–6.
241 Suh DH, Kim BY, Min SU, et al. A multicenter epidemiological study of acne
vulgaris in Korea. Int J Dermatol 2011;50:673–81.
242 Khunger N, Kumar C. A clinico‐epidemiological study of adult acne: is it different from adolescent acne? Indian J Dermatol Venereol Leprol 2012;78:335–41.
243 Suthipinittharm P, Noppakun N, Kulthanan K, et al. Opinions and perceptions
on acne: a community‐based questionnaire study in Thai students. J Med Assoc
Thai 2013;96:952–9.
c90_ref.indd 5
90.5
244 Chiu A, Chon SY, Kimball AB. The response of skin disease to stress: changes
in the severity of acne vulgaris as affected by examination stress. Arch Dermatol
2003;139:897–900.
245 Yosipovitch G, Tang M, Dawn AG, et al. Study of psychological stress, sebum
production and acne vulgaris in adolescents. Acta Derm Venereol 2007;87:135–9.
246 Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female
adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol
2001;15:541–5.
247 Corey KC, Cheng CE, Irwin B, et al. Self‐reported help‐seeking behaviors
and treatment choices of adolescents regarding acne. Pediatr Dermatol
2013;30:36–41.
248 Poli F, Auffret N, Beylot C, et al. Acne as seen by adolescents: results of questionnaire study in 852 French individuals. Acta Derm Venereol 2011;91:531–6.
249 Suthipinittharm P, Noppakun N, Kulthanan K, et al. Opinions and perceptions
on acne: a community‐based questionnaire study in Thai students. J Med Assoc
Thai 2013;96:952–9.
250 Law MP, Chuh AA, Lee A, et al. Acne prevalence and beyond: acne disability
and its predictive factors among Chinese late adolescents in Hong Kong. Clin
Exp Dermatol 2010;35:16–21.
251 Ganceviciene R, Graziene V, Bohm M, et al. Increased in situ expression of melanocortin‐1 receptor in sebaceous glands of lesional skin of patients with acne
vulgaris. Exp Dermatol 2007;16:547–52.
252 Ganceviciene R, Graziene V, Fimmel S, et al. Involvement of the corticotropin‐
releasing hormone system in the pathogenesis of acne vulgaris. Br J Dermatol
2009;160:345–52.
253 Ganceviciene R, Bohm M, Fimmel S, et al. The role of neuropeptides in the multifactorial pathogenesis of acne vulgaris. Dermatoendocrinology 2009;1:170–6.
254 Albuquerque RG, Rocha MA, Bagatin E, et al. Could adult female acne be associated with modern life? Arch Dermatol Res 2014;306:683–8.
255 Mahe A, Ly F, Aymard G, et al. Skin diseases associated with the cosmetic
use of bleaching products in women from Dakar, Senegal. Br J Dermatol
2003;148:493–500.
256 Kane A, Niang SO, Diagne AC, et al. Epidemiologic, clinical, and therapeutic
features of acne in Dakar, Senegal. Int J Dermatol 2007;46(Suppl. 1):36–8.
257 Plewig G, Fulton JE, Kligman AM. Pomade acne. Arch Dermatol 1970;101:580–4.
258 Mills OH Jr, Kligman AM. Acne detergicans. Arch Dermatol 1975;111:65–80.
259 Gfesser M, Worret WI. Seasonal variations in the severity of acne vulgaris. Int J
Dermatol 1996;35:116–17.
260 Tamer E, Ilhan MN, Polat M, et al. Prevalence of skin diseases among pediatric
patients in Turkey. J Dermatol 2008;35:413–18.
261 Al‐Ameer AM, Al‐Akloby OM. Demographic features and seasonal variations
in patients with acne vulgaris in Saudi Arabia: a hospital‐based study. Int J Dermatol 2002;41:870–1.
262 Jha AK, Gurung D. Seasonal variation of skin diseases in Nepal: a hospital
based annual study of out‐patient visits. Nepal Med Coll J 2006;8:266–8.
263 Hancox JG, Sheridan SC, Feldman SR, et al. Seasonal variation of dermatologic
disease in the USA: a study of office visits from 1990 to 1998. Int J Dermatol
2004;43:6–11.
264 Novy FG. Tropical acne. California Med J 1946;115:274–6.
265 Jones C, Bleehen SS. Acne induced by PUVA treatment. BMJ 1977;ii:866.
266 Nielson EB, Thormann J. Acne‐like eruptions induced by PUVA treatment. Acta
Derm Venereol (Stockh) 1978;58:374–5.
267 Chiba K, Yoshizawa K, Makino I, et al. Comedogenicity of squalene monohydroperoxide in the skin after topical application. J Toxicol Sci 2000;25:77–83.
268 Suh DH, Kwon TE, Youn JI. Changes of comedonal cytokines and sebum secretion after UV irradiation in acne patients. Eur J Dermatol 2002;12:139–44.
269 Ratzer MA. The influence of marriage, pregnancy and childbirth on acne vulgaris. Br J Dermatol 1964;76:165–8.
270 Hızlı D, Kosus A, Kosus N, et al. The impact of birth weight and maternal history on acne, hirsutism, and menstrual disorder symptoms in Turkish adolescent girls. Endocrine 2012;41:473–8.
271 Pandolfi C, Zugaro A, Lattanzio F, et al. Low birth weight and later development of insulin resistance and biochemical/clinical features of polycystic ovary
syndrome. Metabolism 2008;57:999–1004.
272 Mastorakos G, Ilias I. Maternal and fetal hypothalamic–pituitary–adrenal axes
during pregnancy and postpartum. Ann NY Acad Sci 2003;997:136–49.
2 73 Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol
2004;22:360–6.
11 March 2016 7:24 PM
90.6
Chapter 90: Acne
274 Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp
Dermatol 2005;14:143–52.
275 Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of
acne pathogenesis and treatment. Exp Dermatol 2009;18:821–32.
276 Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology
2001;203:277–9.
277 Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory
events are involved in acne lesion initiation. J Invest Dermatol 2003;121:20–7.
278 Freedberg IM, Tomic‐Canic M, Komine M, Blumenberg M. Keratins and the
keratinocyte activation cycle. J Invest Dermatol 2001;116:633–40.
279 Trivedi NR, Gilliland KL, Zhao W, Liu W, Thiboutot DM. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in
inflammation and matrix remodeling. J Invest Dermatol 2006;126:1071–9.
280 Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor‐kappaB
and activator protein‐1 in inflammatory acne lesions in vivo. Am J Pathol
2005;166:1691–9.
281 Choi JJ, Park MY, Lee HJ, et al. TNF‐a increases lipogenesis via JNK and PI3K/
Akt pathways in SZ95 human sebocytes. J Dermatol Sci 2012;65:179–88.
282 Kistowska M, Gehrke S, Jankovic D, et al. IL‐1b drives inflammatory responses to
Propionibacterium acnes in vitro and in vivo. J Invest Dermatol 2014;134:677–85.
283 Kelhälä HL, Palatsi R, Fyhrquist N, et al. IL‐17/Th17 pathway is activated in
acne lesions. PLOS One 2014;9(8):e105238.
284 Alestas T, Ganceviciene R, Fimmel S, Muller‐Decker K, Zouboulis CC. Enzymes
involved in the biosynthesis of leukotriene B(4) and prostaglandin E(2) are
active in sebaceous glands. J Mol Med 2006;84:75–87.
285 Zhang Q, Seltmann H, Zouboulis CC, Travers JB. Activation of platelet‐activating factor receptor in SZ95 sebocytes results in inflammatory cytokine and
prostaglandin E2 production. Exp Dermatol 2006;15:769–74.
286 Neufang G, Furstenberger G, Heidt M, Marks F, Muller‐Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing
cyclooxygenase‐2 in skin. Proc Natl Acad Sci USA 2001;98:7629–34.
287 Zhang Q, Seltmann H, Zouboulis CC, Konger RL. Involvement of PPARgamma
in oxidative stress‐mediated prostaglandin E(2) production in SZ95 human
sebaceous gland cells. J Invest Dermatol 2006;126:42–8.
288 Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of
the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol
2009;19:148–50.
289 Krause K, Schnitger A, Fimmel S, Glass E, Zouboulis CC. Corticotropin‐releasing hormone skin signaling is receptor‐mediated and is predominant in the
sebaceous glands. Horm Metab Res 2007;39:66–70.
290 Zouboulis CC, Seltmann H, Hiroi N, et al. Corticotropin‐releasing hormone: an
autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl
Acad Sci USA 2002;99:7148–53.
291 Thody AJ, Cooper MF, Bowden PE, Meddis D, Shuster S. Effect of alpha‐melanocyte‐stimulating hormone and testosterone on cutaneous and modified
sebaceous glands in the rat. J Endocrinol 1976;71:279–88.
292 Zhang L, Li WH, Anthonavage M, Eisinger M. Melanocortin‐5 receptor: a
marker of human sebocyte differentiation. Peptides 2006;27:413–20.
293 Böhm M, Schiller M, Ständer S, et al. Evidence for expression of melanocortin‐1
receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002;118:533–
9.
294 Bhardwaj R, Becher E, Mahnke K, et al. Evidence for the differential expression of the functional alpha‐melanocyte‐stimulating hormone receptor MC‐1
on human monocytes. J Immunol 2007;158:3378–84.
295 Hartmeyer M, Scholzen T, Becher E, et al. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce
increased levels of IL‐8 upon stimulation with alpha‐melanocyte‐stimulating
hormone. J Immunol 1997;159:1930–7.
296 Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004;22:360–
6.
297 Toyoda M, Nakamura M, Morohashi M. Neuropeptides and sebaceous glands.
Eur J Dermatol 2002;12:422–7.
298 Thielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV and
aminopeptidase N target major pathogenetic steps in acne initiation. J Invest
Dermatol 2007;127:1042–51.
299 Fitz‐Gibbon S, Tomida S, Chiu BH, et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol
2013;133:2152–60.
c90_ref.indd 6
300 Jasson F, Nagy I, Knol AC, et al. Different strains of Propionibacterium
acnes modulate differently the cutaneous innate immunity. Exp Dermatol
2013;22:587–92.
301 Nagy I, Pivarcsi A, Kis K, et al. Propionibacterium acnes and lipopolysaccharide induce the expression of antimicrobial peptides and proinflammatory
cytokines/chemokines in human sebocytes. Microbes Infect 2006;8:2195–205.
302 Nagy I, Pivarcsi A, Koreck A, et al. Distinct strains of Propionibacterium acnes
induce selective human beta‐defensin‐2 and interleukin‐8 expression in human
keratinocytes through toll‐like receptors. J Invest Dermatol 2005;124:931–8.
303 Schaller M, Loewenstein M, Borelli C, et al. Induction of a chemoattractive proinflammatory cytokine response after stimulation of keratinocytes with Propionibacterium acnes and coproporphyrin III. Br J Dermatol 2005;153:66–71.
304 Agak GW, Qin M, Nobe J, et al. Propionibacterium acnes induces an IL‐17
response in acne vulgaris that is regulated by vitamin A and vitamin D. J Invest
Dermatol 2014;134:366–73.
305 Kistowska M, Meier B, Proust T, et al. Propionibacterium acnes promotes Th17
and Th17/Th1 responses in acne patients. J Invest Dermatol 2015;135:110–18.
306 Kistowska M, Gehrke S, Jankovic D, et al. IL‐1b drives inflammatory
responses to Propionibacterium acnes in vitro and in vivo. J Invest Dermatol
2014;134:677–85.
307 Li ZJ, Choi DK, Sohn KC, et al. Propionibacterium acnes activates the NLRP3
inflammasome in human sebocytes. J Invest Dermatol 2014;134:2747–56.
308 Kim J. Review of the innate immune response in acne vulgaris: activation of
Toll‐like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 2005;211:193–8.
309 Georgel P, Crozat K, Lauth X, et al. A toll‐like receptor 2‐responsive lipid effector pathway protects mammals against skin infections with gram‐positive bacteria. Infect Immun 2005;73:4512–21.
310 Oeff MK, Seltmann H, Hiroi N, et al. Differential regulation of Toll‐like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes.
Dermatology 2006;213:266.
311 Selway JL, Kurczab T, Kealey T, Langlands K. Toll‐like receptor 2 activation
and comedogenesis: implications for the pathogenesis of acne. BMC Dermatol
2013;13:10.
312 Bakry OA, Samaka RM, Sebika H, Seleit I. Toll‐like receptor 2 and P. acnes:
do they trigger initial acne vulgaris lesions? Anal Quant Cytopathol Histpathol
2014;36:100–10.
313 Chronnell CMT, Ghali LR, Ali RS, et al. Human beta defensin‐1 and ‐2 expression in human pilosebaceous units: upregulation in acne vulgaris lesions. J
Invest Dermatol 2001;117:1120–5.
314 Lee DY, Yamasaki K, Rudsil J, et al. Sebocytes express functional cathelicidin
antimicrobial peptides and can act to kill Propionibacterium acnes. J Invest Dermatol 2008;128:1863–6.
315 Graham GM, Farrar MD, Cruse‐Sawyer JE, Holland KT, Ingham E. Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol 2004;150:421–8.
316 McDowell A, Valanne S, Ramage G, et al. Propionibacterium acnes types I and
II represent phylogenetically distinct groups. J Clin Microbiol 2005;43:326–34.
317 Georgel P, Crozat K, Lauth X, et al. A toll‐like receptor 2‐responsive lipid effector pathway protects mammals against skin infections with gram‐positive bacteria. Infect Immun 2005;73:4512–21.
318 Harrison WJ, Bull JJ, Seltmann H, Zouboulis CC, Philpott MP. Expression of
lipogenic factors galectin‐12, resistin, SREBP‐1, and SCD in human sebaceous
glands and cultured sebocytes. J Invest Dermatol 2007;127:1309–17.
319 Nakatsuji T, Kao MC, Fang JY, et al. Antimicrobial property of lauric acid
against Propionibacterium acnes: its therapeutic potential for inflammatory
acne vulgaris. J Invest Dermatol 2009;129:2480–8.
320 Nakatsuji T, Kao MC, Zhang L, et al. Sebum free fatty acids enhance the innate
immune defense of human sebocytes by upregulating beta‐defensin‐2 expression. J Invest Dermatol 2010;130:985–94.
321 Sneddon J, Sneddon I. Acne excoriée: a protective device. Clin Exp Dermatol
1983;8:65–8.
322 Gupta MA, Gupta AK, Schork NJ. Psychosomatic study of self‐excoriative
behaviour among male acne patients: preliminary observations. Int J Dermatol
1994;33:846–8.
323 Gupta MA, Gupta AK. Psychodermatology: an update. J Am Acad Dermatol
1996;34:1030–46.
324 Kranke B, Brabek E, Derhaschnig J, et al. Acne excoriata: look for allergy! Dermatology 2001;203:256–7.
11 March 2016 7:24 PM
References
325 Gieler U, Consoli SG, Tomas‐Aragones L, et al. Self‐inflicted lesions in dermatology: terminology and classification. A position paper from the European Society for Dermatology and Psychiatry (ESDaP). Acta Derm Venereol
2013;93:4–12.
326 Shenefelt PD. Using hypnosis to facilitate resolution of psychogenic excoriations in acne excoriee. Am J Clin Hypn 2004;46:239–45.
327 Kent A, Drummond LM. Acne excoriee: a case report using habit reversal. Clin
Exp Dermatol 1989;14:163–4.
328 Bowes LE, Alster TS. Treatment of facial scarring and ulceration resulting from
acne excoriée with the 585‐nm pulsed dye laser irradiation and cognitive psychotherapy. Dermatol Surg 2004;30:934–8.
329 Cotterill JA. Dermatological non‐disease: a common and potentially fatal disturbance of cutaneous body image. Br J Dermatol 1981;104:611–19.
330 Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol
1997;137:246–50.
331 Hull SM, Cunliffe WJ, Hughes BR. Treatment of the depressed and dysmorphophobic acne patient. Clin Exp Dermatol 1991;16:210–11.
332 Strumia R. Skin signs in anorexia nervosa. Dermatoendocrinology 2009;1:268–70.
333 Peachey RDG, Matthews CNA. ’Fiddler’s neck’. Br J Dermatol 1978;98:669–74.
334 Goldman L. Turtleneck shirt and sweater acne [Letter]. Arch Dermatol
1977;113:109.
335 MacGregor AJ, Cunliffe WJ, Tan SG. Acne mechanica. BMJ 1976;i:130–1.
336 Strauss RM, Harrington CI. Stump acne: a new variant of ance mechanica and
a cause of immobility. Br J Dermatol 2001;144:647–8.
337 Daley TD. Intraoral sebaceous hyperplasia. Diagnostic criteria. Oral Surg Oral
Med Oral Pathol 1993;75:343–7.
338 Monk BE. Fordyce spots responding to isotretinoin therapy. Br J Dermatol
1993;129:355.
339 Campo‐Candriani J, Villarreal‐Rodriquez A, Quinones‐Fernandez AG, et al.
Treatment of Fordyce spots with CO2 laser. Dermatol Surg 2003;29:869–71.
340 Tsuji T, Yamauchi R. Areolar sebaceous hyperplasia with a Fordyce’s spot‐like
lesion. J Dermatol 1994;21:524–6.
341 Cunliffe WJ, Ead RD, Perera WHD, et al. An acne‐free naevus. Br J Dermatol
1977;96:287–90.
342 Betiman C. Über den Naevus acneiformis. Arch Dermatol Syphilol 1906;80:63–6.
343 White CJ. Naevus follicularis keratosus. J Cutan Dis 1914;32:187–90.
344 Marsden RA, Fleming K, Dawber RPR. Comedo naevus of the palm: a sweat
duct naevus? Br J Dermatol 1979;101:717–22.
345 Abdel‐Aal H, Abdel‐Aziz AHM. Nevus comedonicus: report of three cases
localized on glans penis. Acta Derm Venereol (Stockh) 1975;55:78–80.
346 Beck MH, Dave VK. Extensive nevus comedonicus. Arch Dermatol
1980;116:1048–50.
347 Barsky S, Doyle JA, Winkelmann RK. Nevus comedonicus with epidermolytic
hyperkeratosis. A report of four cases. Arch Dermatol 1981;117:86–9.
348 Baxter K, Highet A, Cunliffe WJ. An unusual late onset closed‐comedone naevus: successful therapy with light cautery and a topical retinoid. J Dermatol
Treat 2004;15:58–9.
349 Munro CS, Wilkie AO. Epidermal mosaicism producing localized acne: somatic
mutation in FGFR2. Lancet 1998;352:704–5.
350 Melnik B, Vakilzadeh F, Aslandis C, et al. Unilateral segmental nevus: a model
disorder towards understanding FGFR2 function in acne? Br J Dermatol
2008;158:1397–9.
351 Mehregan AH, Pinkus H. Life history of organoid naevi. Special reference to
naevus sebaceous of Jadassohn. Arch Dermatol 1965;91:574–88.
352 Lantis S, Leyden JE, Thew M, Heaton C. Naevus sebaceous of Jadassohn: part
of a new neurocutaneous syndrome? Arch Dermatol 1968;98:117–23.
353 Fergin PE, Chu AC, MacDonald DM. Basal cell carcinoma complicating naevus
sebaceous. Clin Exp Dermatol 1981;6:111–15.
354 Weigl L, Eberlein‐Konig B, Ring J. Eccrine syringofibroadenoma developing in
a sebaceous naevus. Br J Dermatol 2000;142:1049–50.
355 Rendlemann L, Stone MS. An unusual hematopoietic proliferation seen in a
nevus sebaceous. J Am Acad Dermatol 2000;42:881–2.
356 Stefanidou M, Ioannidou D, Tosca A. Unilateral nodular elastosis with cysts
and comedones (Favre–Racouchot syndrome). Dermatology 2001;207:270–1.
357 De Berker DAR, Taylor AE, Quinn AG, et al. Sebaceous hyperplasia in organ
transplant recipients: shared aspects of hyperplastic and dysplastic processes?
J Am Acad Dermatol 1996;35:696–9.
c90_ref.indd 7
90.7
358 Ahassi D, Gonzalez E, Anderson RR, et al. Elucidating the pulsed‐dye laser
treatment of sebaceous hyperplasia in vivo with real‐time confocal scanning
laser microscopy. J Am Acad Dermatol 2000;43:49–53.
359 No D, McClaren M, Chotzen V. Sebaceous hyperplasia treated with a 1450 nm
diode laser. Dermatol Surg 2004;30:383–4.
360 Gollnick H, Orfanos CE. Front facial picture of a lady with familial nevoid sebaceous hyperplasia before and after treatment with isotretinoin. In: Wilkinson
DS, Mascaro JM, Orfanos CE, eds. Clinical Dermatology. The CMD Case Collection. Stuttgart: Schattauer, 1987:350–2.
361 Richey DF. Aminolevulinic acid photodynamic therapy for sebaceous gland
hyperplasia. Dermatol Clin 2007;25:59–65.
362 Torré D. Multiple sebaceous tumors. Arch Dermatol 1968;98:549–52.
363 Davis DA, Cohen PR. Genitourinary tumors in men with the Muir–Torré syndrome. J Am Acad Dermatol 1995;33:909–12.
364 Schwartz RA, Torré DP. The Muir–Torré syndrome: a 25 year retrospect. J Am
Acad Dermatol 1995;33:90–104.
365 Hall NR, Murday VA, Chapman P, et al. Genetic linkage in Muir–Torré syndrome to the same chromosomal region as cancer family syndrome. Eur J Cancer 1994;30A:180–2.
366 Lachiewicz AM, Wilkinson JM, Groben P, et al. Muir–Torre syndrome. Am J Clin
Dermatol 2007;8:215–19.
367 Brauninger GE, Hood CI, Worthen DM. Sebaceous carcinoma of lid margin
masquerading as cutaneous horn. Arch Ophthalmol 1973;90:380–1.
368 Matsumoto CS, Nakatsuka K, Matsuo K, et al. Sebaceous carcinoma responds to
radiation therapy. Ophthalmologica 1995;209:280–3.
369 Saito A, Tsutsumida A. Sebaceous carcinoma of the eyelids: a review of 21 ases.
J Plast Reconstr Aesthetic Surg 2008;61:1328–31.
370 Amerlinck F. Sébocystomatose héréditaire. Arch Belg Dermatol Syphiligr
1949;5:187–91.
371 Egbert DM, Price NM, Segal RJ. Steatocystoma multiplex. Report of a florid
case and a review. Arch Dermatol 1979;115:334–5.
372 Plewig G, Wolff HH, Braun‐Falco D. Steatocytoma multiplex: anatomic re‐
evaluation, electron microscopy, and autoradiography. Arch Dermatol Res
1982;272:363–80.
373 Cho S, Chang SE, Choi JH, et al. Clinical and histological features of 64 cases of
steatocystoma multiplex. J Dermatol 2002;29:152–6.
374 Murray FA. Congenital anomalies of nails associated with teeth erupted at
birth. Br J Dermatol 1921;33:409–16.
375 Jackson AD, Lawler SD. Pachyonychia congenita: a report on six cases in one
family. Ann Eugen 1951;16:142–6.
376 Clementi M, Cardin de Stefani E, Dei Rossi C, et al. Pachyonychia congenita Jackson–Lawler type: a distinct malformation syndrome. Br J Dermatol
1986;114:367–70.
377 Oh SW, Kim MY, Lee JS, et al. Keratin 17 mutation in pachyonychia congenita type 2 with early onset steatocystoma multiplex and Hutchinson‐like tooth
deformity. J Dermatol 2006;33:161–4.
378 McDonald RM, Reed WB. Natal teeth and steatocystoma multiplex complicated by hidradenitis suppurativa. Arch Dermatol 1975;112:1132–4.
379 Moon SE, Lee YS, Young JI. Eruptive vellus hair cyst and steatocystoma multiplex in a patient with pachyonychia congenita. J Am Acad Dermatol 1994;30:275–
6.
380 McLean WHI, Rugg EL, Lunny DP, et al. Keratin 16 and keratin 17 mutations
cause pachyonychia congenita. Nat Genet 1995;9:273–8.
381 Smith FJD, Corden LD, Rugg EL, et al. Missense mutations in keratin 17 cause
either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex. J Invest Dermatol 1997;108:220–3.
382 Feng YG, Xiao SX, Ren XR, et al. Keratin 17 mutation in pachyonychia congenita
type 2 with early onset sebaceous cysts. Br J Dermatol 2003;148:452–5.
383 King NM, Lee AMP. Natal teeth and steatocystoma multiplex: a newly recognised syndrome. J Craniofac Genet Dev Biol 1987;7:311–17.
384 Lee SJ, Choe YS, Park BC, et al. The vein hook successfully used for eradication
of steatocystoma multiplex. Dermatol Surg 2007;33:82–6.
385 Rossi R, Cappugi P, Battini M, et al. CO2 laser therapy in a case of steatocystoma
multiplex with prominent nodules on the face. Int J Dermatol 2003;42:302–4.
386 Hwang S, Schwartz RA. Keratosis pilaris: a common follicular hyperkeratosis.
Cutis 2008;82:177–80.
387 Poskitt L, Wilkinson JD. Natural history of keratosis pilaris. Br J Dermatol
1994;130:711–13.
11 March 2016 7:24 PM
90.8
Chapter 90: Acne
388 Zouboulis CC, Stratakis CA, Gollnick HP, et al. Keratosis pilaris/ulerythema
ophryogenes and 18p depletion: is it possible that the LAMA1 gene is involved?
J Med Genet 2001;38:127–8.
389 Schmitt JV, Lima BZ, Souza MCMR, et al. Keratosis pilaris and prevalence of
acne vulgaris a cross sectional study. An Bras Dermatol 2014;89:91–5.
390 Fulton JE, McGinley K, Leyden J, et al. Gram‐negative folliculitis in acne vulgaris. Arch Dermatol 1968;98:349–53.
391 Leyden JJ, Marples RR, Mills OK. Gram negative folliculitis: a complication of
antibiotic therapy in acne vulgaris. Br J Dermatol 1973;88:533–8.
392 Leyden JJ, McGinley KJ, Mills OH. Pseudomonas aeruginosa Gram negative
folliculitis. Arch Dermatol 1979;115:1203–4.
393 James WD, Leyden JJ. Treatment of Gram‐negative folliculitis with isotretinoin: positive clinical and microbiologic response. J Am Acad Dermatol
1985;12:319–24.
394 Plewig C, Nikolowski J, Wolff HH. Action of isotretinoin in acne rosacea and
Gram‐negative folliculitis. J Am Acad Dermatol 1982;6:766–85.
395 Boni R, Nehroff B. Treatment of Gram negative folliculitis in acne patients. Am
J Clin Dermatol 2003;4:273–6.
396 Ford CP, Ive FA, Midgley G. Pityrosporum folliculitis and ketoconazole. Br J
Dermatol 1982;107:691–5.
397 Faergemann J. Pityrosporum infections. J Am Acad Dermatol 1994;31(3 Pt
2):S18–20.
398 Hughes BR, Cunliffe WJ. Development of folliculitis and pyoderma gangrenosum in association with abdominal pain in a patient following treatment with
isotretinoin. Br J Dermatol 1990;122:683–7.
399 Esmat SM, Abdel Hay RM, Abu Zeid OM, et al. The efficacy of laser‐assisted
hair removal in the treatment of acne keloidalis nuchae: a pilot study. Eur J
Dermatol 2012;22:645–5.
400 Alexis A, Heath CR, Halder RM. Folliculitis keloidalis nuchae and pseudofolliculitis barbae: are prevention and effective treatment within reach? Dermatol
Clin 2014;32:183–91.
401 Karakuzu A, Erdem, T, Aktas A, et al. A case of folliculitis decalvans involving
the beard, face and nape. J Dermatol 2001;28:329–31.
402 Powell JJ, Dawber RPR, Gatter K. Folliculitis decalvans including tufted
folliculitis: clinical, histological and therapeutic findings. Br J Dermatol
1999;140:328–33.
403 Brooke RC, Griffiths CEM. Folliculitis decalvans. Clin Exp Dermatol 2001;26:120–
2.
404 Kaur S, Kanwar AJ. Folliculitis decalvans: successful treatment with a combination of rifampicin and topical mupirocin. J Dermatol 2002;29:180–1.
405 Gemmeke A, Wollina U. Folliculitis decalvans of the scalp: response to triple
therapy with isotretinoin, clindamycin and prednisolone. Acta Dermatovenereol
Alp Panonica Adriat 2006;15:184–6.
406 Abdeck D, Korting HC, Braun‐Falco O. Folliculitis decalvans. Long lasting
response to combined therapy with fusidic acid and zinc. Acta Derm Venereol
1992;72:143–5.
407 Kunte C, Loeser C, Wolff H. Folliculitis spinulosa decalvans: successful treatment with dapsone. J Am Acad Dermatol 1998;39:891–3.
408 Smith EP, Hardaway CA, Graham BS, et al. Folliculitis decalvans treated with
radiation therapy. Cutis 2006;78:162–4.
409 Sivakumaran S, Meyer P, Burrows NP. Dissecting folliculitis of the scalp with
marginal keratitis. Clin Exp Dermatol 2001;26:490–2.
410 Kobayashi H, Aiba S, Tagami H. Successful treatment of dissecting cellulitis
and acne conglobata with oral zinc. Br J Dermatol 1999;141:1137–8.
411 Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Perifolliculitis capitis abscedens et suffodiens successfully controlled with topical isotretinoin. Eur
J Dermatol 2003;13:192–5.
412 Ljubojevic S, Pasic A, Lipozencic J, et al. Perifolliculitis capitis abscendens et
suffodiens. J Eur Acad Dermatol Venereol 2005;19:719–21.
413 Scheinfeld NS. A case of dissecting cellulitis and a review of the literature. Dermatol Online J 2003;9(1):8.
414 Chicarilli ZN. Follicular occlusion triad: hidradenitis suppuritiva, acne conglobate and dissecting cellulitis of the scalp. Ann Plast Surg 1987;18:230–7.
415 Prasad SC, Bygum A. Successful treatment with alitretinoin of dissecting cellulitis of the scalp in keratitis–ichthyosis–deafness syndrome. Acta Derm Venereol
2013;93:473–4.
416 Jansen T, Altmeyer P, Plewig G. Acne inversa (alias hidradenitis suppurativa). J
Eur Acad Dermatol Venereol 2001;15:532–40.
c90_ref.indd 8
417 Von der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001;144:809–13.
418 Von der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000;142:947–53.
419 Palmer RA, Keefe M. Early onset hidradenitis suppurativa. Clin Exp Dermatol
2001;26:501–3.
420 Georgousas K, Kocsard E. Micropapular sarcoidal facial eruption in a child.
Gianotti‐type perioral dermatitis. Acta Derm Venereol (Stockh) 1978;58:433–6.
421 Schlappner OLA, Shelley WB, Ruberg RL, Dudrick SJ. Acute papulopustular acne, associated with prolonged intravenous hyperalimentation. JAMA
1972;219:877–80.
422 Kossard S, Collins A, McCrossin I. Necrotizing lymphocytic folliculitis: the early lesion of acne necrotica (varioliformis). J Am Acad Dermatol
1987;16:1007–14.
423 Maibach HI. Acne necroticans (varioliformis) versus Propionibacterium acnes
folliculitis. J Am Acad Dermatol 1989;21:323.
424 Barratt H, Hamilton F, Car J, et al. Outcome measures in acne vulgaris: systematic review. Br J Dermatol 2009;160:132–6.
425 Patwardhan SV, Kaczvinsky JR, Joa JF, Canfield D. Auto‐classification of acne
lesions using multimodal imaging. J Drugs Dermatol 2013;12:746–56.
426 Warburton K, Whitehouse H, El‐Naes R, et al. How people with acne decide if
their treatment is working. Br J Dermatol 2014;171:38.
427 O’Brien SC, Lewis JB, Cunliffe WJ. The Leeds revised acne grading scale. J Dermatol Treat 1998;9:215–20.
428 Tan J, Tang J, Fung K, et al. Development and validation of a comprehensive
acne severity scale (CASS). J Cutan Med Surg 2007;11:211–16.
429 Lucky AW, Barber BL, Girman CJ, et al. A multirotor validation study to assess
the reliability of acne lesion counting. J Am Acad Dermatol 1996;35:559–65.
430 Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg
1998;17:291–6.
431 Gupta MA, Johnson AM, Gupta AK. The development of an Acne Quality of
Life Scale: reliability, validity and relation to the subjective acne severity in mild
to moderate acne vulgaris. Acta Derm Venereol (Stockh) 1998;78:451–8.
432 Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol 1995;32(5 Pt 3):S15–25.
433 Agache P. Sebaceous functions assessment. In: Agache P, Philippe H, eds. Measuring the Skin. Berlin: Springer‐Verlag, 2004:281.
434 Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin
conditions. Soc Sci Med 1985;20:425–9.
435 Cunliffe WJ. Unemployment and acne. Br J Dermatol 1986;115:386.
436 Wu SF, Kinder BN, Trunnell TN, et al. Role of anxiety and anger in acne patients:
a relationship with the severity of the disorder. J Am Acad Dermatol 1988;18:325–
33.
437 Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison
with medical conditions using questionnaires. Br J Dermatol 1999;140:672–6.
438 Feingolg A. Good‐looking people are not what we think. Psychol Bull
1992;111:304–41.
439 Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology
patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846–50.
440 Garrie S, Garrie E. Anxiety and skin diseases. Cutis 1979;22:205–8.
441 Patel MJ, Antony A, Do TT, et al. Atrophic acne scars may arise from both inflammatory and non‐inflammatory acne lesions. J Invest Dermatol 2010;130(Suppl.
1s):S58.
442 Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring
and its incidence. Clin Exp Dermatol 1994;1:303–8.
443 Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring: a
comparison of the responses in lesions from patients prone and not prone to
scar. Br J Dermatol 2004;150:72–81.
444 Finlay AY, Torres V, Kang S, et al. Classification of acne scars is difficult even for
acne experts. J Eur Acad Dermatol Venereol 2013;27:391–3.
445 Verdi DP, Saqueton AC. Perifollicular elastolysis. Br J Dermatol 1970;83:143–50.
446 Leider M. Osteoma cutis as a result of severe acne vulgaris of long duration.
Arch Dermatol Syphilol 1950;62:405–7.
447 MacGregor A. Calcification in scars of healed acne vulgaris. Oral Surg Oral Med
Oral Pathol 1971;32:829–30.
448 Camcho‐Martinez F, Winkelmann RK. Solid facial edema as a manifestation of
acne. J Am Acad Dermatol 1990;22:129–30.
11 March 2016 7:24 PM
References
449 Tosti A, Guerra L, Bettoli V. Solid facial edema as a complication of acne vulgaris in twins. J Am Acad Dermatol 1987;17:843–4.
450 Uhara H, Kawachi S, Saida T. Solid facial edema in a patient with rosacea. J
Dermatol 2000;27:214–16.
451 Freidman SJ, Fox BJ, Albert HL. Solid edema as a complication of acne vulgaris:
treatment with isotretinoin. J Am Acad Dermatol 1986;15:286–9.
452 Jungfer B, Jansen T, Przbilla G. Solid facial edema of acne: successful treatment
with isotretinoin and ketotifen. Dermatology 1993;187:34–7.
453 Helander I, Aho HJ. Solid facial edema as a complication of acne vulgaris:
treatment with isotretinoin and clofazimine. Acta Derm Venereol (Stockh)
1987;67:535–7.
454 Basler RGW, Taylor WB, Peacor DR. Post‐acne osteoma. Arch Dermatol
1974;110:113–14.
455 Monteiro M, Koblenzer C. Multiple osteoma cutis lesions associated with acne.
Int J Dermatol 2000;39:553–4.
456 Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some aetiological,
clinical and therapeutic strategies. Dermatology 2003;206:11–16.
457 Cohen AD, Chetov T, Cagnano E, et al. Treatment of multiple miliary osteoma
cutis of the face with local application of tretinoin (all‐trans‐retinoic‐acid): a
case report and review of the literature. J Dermatol Treat 2001;12:171–3.
458 Smith CG, Galser DA. Treatment of multiple miliary osteoma cutis with tretinoin gel. J Am Acad Dermatol 1999;41:500.
459 Fulton JE Jr. Dermabrasion‐Loo‐punch‐excision technique for the treatment of
acne‐induced osteoma cutis. J Dermatol Surg Oncol 1987;13:655–9.
460 Altman JF, Nehal KS, Halpern AC, et al. Treatment of miliary osteoma cutis with
incision, curettage and primary closure. J Am Acad Dermatol 2001;44:96–9.
461 Baskan EB, Turan H, Tunali S, et al. Miliary osteoma cutis of the face: treatment
with needle microincision‐extirpation method. J Dermatol Treat 2007;18:252–4.
462 Ochsendorf FR, Kaufmann R. Erbium‐YAG laser‐assisted treatment of miliary
osteoma cutis. Br J Dermatol 1998;138:371–2.
463 Ochsendorf FR, Kaufmann R. Erbium‐YAG laser ablation for osteoma cutis:
modification of approach. Arch Dermatol 1999;135:1416.
464 Mobayen MM, Copeman PWM. Multiple pyogenic granuloma in secondarily
infected cystic acne. Clin Exp Dermatol 1983;8:107–9.
465 Miller RAW, Ross JB. Multiple granulation tissue lesions occurring in isotretinoin treatment of acne vulgaris. J Am Acad Dermatol 1985;12:888–9.
466 Cunliffe WJ, Shuster S. Pathogenesis of acne. Lancet 1969;i:685–7.
467 Gollnick HP, Finlay AY, Shear N, et al. Can we define acne as a chronic disease?
If so, how and when? Am J Dermatol 2008;9:279–84.
468 Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997;336:1156–62.
469 Cunliffe WJ, Clayden AD, Gould D, et al. Acne vulgaris: its aetiology and treatment. A review. Clin Exp Dermatol 1981;6:461–9.
470 Thiboutot D. New treatment and therapeutic strategies for acne. Arch Fam Med
2000;9:179–87.
471 Nast A, Dréno B, Bettoli V, et al. European evidence‐based (S3) guidelines for
the treatment of acne. J Eur Acad Dermatol Venereol 2012;26(Suppl. 1):1–29.
472 Dreno B, Bettoli V, Ochsendorf F, et al. An expert view on the treatment of acne
with systemic antibiotics and/or oral isotretinoin in the light of the new European recommendations. Eur J Dermatol 2006;15:565–71.
473 Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective
in the treatment of acne vulgaris: a multicentre double‐blind randomised controlled study. Cutis 1999;63:349–53.
474 Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once‐daily
tazarotene 0.0% gel vs once‐daily 0.025% gel in the treatment of facial acne vulgaris: a randomised trial. Cutis 2001;67:17–27.
475 Christophers E, Wolfe HH. Effect of vitamin A acid on skin: in vivo and in vitro
studies. Acta Derm Venereol (Stockh) 1975;74:42–53.
476 Lyons RE. Comparative effectiveness of benzoyl peroxide and tretinoin in acne
vulgaris. Int J Dermatol 1978;17:246–51.
477 Leyden J, Shalita AR. Rational therapy for acne vulgaris: an update on topical
treatment. J Am Acad Dermatol 1986;15:907–15.
478 Bouclier M, Chatelus A, Ferracin J, et al. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model
using a standardized image analysis technique. Skin Pharmacol 1991;4:65–73.
479 Liu PT, Krutzik SR, Kim J, et al. Cutting edge: all‐trans retinoic acid down regulates TLR2 expression and function. J Immunol 2005;174:2467–70.
480 Tenaud I, Khamamari A, Dreno B. In vitro modulation of TLR‐2, CD1d and
IL‐10 by adapalene on normal human skin and inflammatory lesions. Exp Dermatol 2007;16:500–6.
c90_ref.indd 9
90.9
481 Jones DA. The potential immunomodulatory effects of topical retinoids. Dermatol Online J 2005;11(1):3.
482 Lehman HP, Andrews JS, Robinson KA, Holloway VL, Goodman SN. Management of acne. Evidence Report/Technology Assessment No. 17. Rockville, MD:
Agency for Healthcare Research and Quality, 2001.
483 Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne
vulgaris: a meta‐analysis of five randomised trials. Br J Dermatol 1998;139(Suppl.
52):48–56.
484 Cunliffe WJ, Holland KT. The effect of benzoyl peroxide on acne. Acta Derm
Venereol (Stockh) 1981;61:267–9.
485 Bojar RA, Cunliffe WJ, Holland KT. The short‐term treatment of acne vulgaris
with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995;132:204–8.
486 Fulton JE, Farzad‐Batshandeth A. Studies on the mechanism of action of topical
benzoyl peroxide in acne vulgaris. J Cutan Pathol 1974;1:194–200.
487 Handojo I. The combined use of topical benzoyl peroxide and tretinoin in the
treatment of acne vulgaris. Int J Dermatol 1979;18:489–96.
488 Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate
the efficacy and safety of topical dapsone gel 5% in the treatment of acne vulgaris. J Am Acad Dermatol 2007;56:439e1–10.
489 Silva A, Gollnick H, Detmar M, et al. Effects of azelaic acid on sebaceous gland,
sebum excretion rate and keratinization pattern in human skin. Acta Derm
Venereol (Stockh) 1989;143:20–30.
490 Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream
in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989;143:35–9.
491 Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of
adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris. J
Am Acad Dermatol 1996;34:482–5.
492 Alirezai M, Meynadier J, Jablonski S, et al. Étude comparative de l’efficacité
de la tolérance des gels d’apalana à 0.1% et 0.03% et d’un gel de trétinoine à
0.025%. Arch Dermatol Vénéréol 1996;123:165–70.
493 Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of
adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a
multicenter trial. J Am Acad Dermatol 1996;34:482–5.
494 Caron D, Sorba V, Kerrouche N, Clucas A. Split‐face comparison of adapalene
0.1% gel and tretinoin 0.025% gel in acne patients. J Am Acad Dermatol 1997;36(6
Pt 2):S110–12.
495 Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective
in the treatment of acne vulgaris: a multicentre double‐blind randomised controlled study. Cutis 1999;63:349–53.
496 Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once‐daily
tazarotene 0.1% gel versus once‐daily tretinoin 0.025% gel in the treatment of
facial acne vulgaris: a randomized trial. Cutis 2001;67(6 Suppl.):4–9.
497 Elbaum DJ. Comparison of the stability and safety of topical isotretinoin and
topical tretinoin and their efficacy in acne. J Am Acad Dermatol 1988;19:486–91.
498 Schaefer H. Penetration and percutaneous absorption of topical retinoids. A
review. Skin Pharmacol 1993;6:17–23.
499 Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide, 5%
erythromycin gel, 3% gel and erythromycin 4% zinc 1–2% solution in the treatment of acne vulgaris. Br J Dermatol 1997;136:235–8.
500 Eady EA, Cope JH, Jones DN, et al. Topical antibiotics for the treatment of acne:
a critical evaluation of the literature on their clinical benefit and comparative
efficacy. J Dermatol Treat 1990;1:215–26.
501 Garner SE, Eady EA, Popescu C, Newton J, Li WA. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2003;(1):CD002086.
502 Garner SE. Acne vulgaris. In: Williams H, ed. Evidence‐Based Dermatology. London: BMJ Publishing, 2003:87–114.
503 Richter JR, Forstrum LR, Kiistala UO, et al. Efficacy of the 1.2% clindamycin
phosphate, 0.025% tretinoin gel formulation and a proprietary 0.025% gel
formulation in the topical control of facial acne. J Eur Acad Dermatol Venereol
1998;11:227–33.
504 Bernstein JE, Lorincz AL. The effects of topical nicotinamide, tetracycline
and dapsone and potassium iodide‐induced inflammation. J Invest Dermatol
1988;74:257–8.
505 Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate
the efficacy and safety of dapsone gel, 5% for the treatment of acne. J Am Acad
Dermatol 2007;56:439e1–10.
11 March 2016 7:24 PM
90.10
Chapter 90: Acne
506 Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of
acne vulgaris: safety and efficacy of long‐term (1 year) treatment. J Drugs Dermatol 2007;6:981–7.
507 Holland KT, Bojar RA. Antimicrobial effects of azelaic acid. J Dermatol Treat
1993;4(Suppl. 1):S8–11.
508 Leeming JP, Holland KT, Bojar RA. The in vitro antimicrobial effect of azelaic
acid. Br J Dermatol 1986;115:551–6.
509 Olsen TE. Therapy of acne. Med Clin North Am 1982;66:851–77.
510 Sykes NL, Webster GF. Acne: a review of optimum treatment. Drugs
1994;48:59–70.
511 Stern RS. Acne therapy: medication use and sources of care in office‐based
practice. Arch Dermatol 1996;132:776–80.
512 Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol
1961;73:367–70.
513 Plewig G, Schill WB, Hofmann C. Orale Behandlung mit Tretinoin, andrologisone, trichologisone, opthalmologisone Befunde und Therapieergeb‐nisse bei
Akne. Arch Dermatol Res 1979;265:37–47.
514 Thiboutot D. Acne: an overview of clinical research findings. Dermatol Clin
1997;15:97–109.
515 Anon. Is minocycline overused in acne? Drug Ther Bull 2006;44:60–4.
516 McManus P, Iheanacho I. Don’t use minocycline as first line oral antibiotic in
acne. BMJ 2007;334:154.
517 Knowles SR, Shear NH. Cutaneous drug reactions with systemic features. In:
Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy, 2nd edn. Philadelphia: Saunders Elsevier, 2007:977–87.
518 Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure
necessitating liver transplantation. Am J Gastroenterol 2000;95:560–1,
519 Ozolins M, Eady EA, Avery A, et al. A cost‐effectiveness rationale for the selection of antimicrobial therapy in acne: a randomized controlled trial. Br J Dermatol 2002;147:13–18.
520 Fernandez‐Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol
2000;39:45–50.
521 Amin K, Riddle CC, Aires DJ, et al. Common and alternative oral therapies for
acne vulgaris: a review. J Drugs Dermatol 2007;79:873–80.
522 Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J
Am Acad Dermatol 1988;19:431–42.
523 Carraso DA, Vander Straten M, Tyring SK. A review of antibiotics in dermatology. J Cutan Med Surg 2002;6:128–50.
524 Lasson HE, Price AB. Pseudomembranous colitis: presence of clostridial toxin.
Lancet 1977;ii:1312–14.
525 Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne
vulgaris. J Drugs Dermatol 2006;17:217–21.
526 Bhambri S, Del Rosso JQ, Desai A. Oral trimethoprim in the treatment of acne
vulgaris. Cutis 2007;79:430–4.
527 Bottomley WW, Cunliffe WJ. Oral trimethoprim as a third‐line antibiotic in the
management of acne vulgaris. Dermatology 1993;187:193–6.
528 Cunliffe WJ, Aldana OL, Goulden V. Oral trimethoprim: a relatively safe and
successful third‐line treatment for acne vulgaris. Br J Dermatol 1999;141:757–8.
529 Gibson JR, Darley CR, Harvey SG, et al. Oral trimethoprim versus oxytetracycline in the treatment of inflammatory acne vulgaris. Br J Dermatol
1982;107:221–4.
530 Remlinger KA. Hematologic toxicity of drug therapy. In: Wolverton SE, ed.
Comprehensive Dermatologic Drug Therapy, 2nd edn. Philadelphia: Saunders
Elsevier, 2007:901–3.
531 Archer J, Archer D. Oral contraceptive efficacy and antibiotic interaction: a
myth debunked. J Am Acad Dermatol 2002;46:917–23.
532 Weaver K, Glasier A. Interaction between broad spectrum antibiotics and
the combined oral contraceptive pill. A literature review. Contraception
1999;59:71–8.
533 Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral
antibiotics. J Am Acad Dermatol 1997;36:705–10.
534 London BM, Lookingbill DP. Frequency of pregnancy in acne patients taking
oral antibiotics and oral contraceptives [Letter]. Arch Dermatol 1994;130:392–3.
535 Ross JI, Snelling AM, Carnegie E, et al. Antibiotic resistance: lessons from
Europe. Br J Dermatol 2003;148:467–78.
536 Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria
in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989;121:51–7.
c90_ref.indd 10
537 Gardner KJ, Cunliffe WJ, Eady EA, et al. Variation in comedonal antibiotic concentrations following applications of topical tetracycline for acne vulgaris. Br J
Dermatol 1994;131:649–54.
538 Layton AM, Hughes BR, Hull SM, et al. Seborrhoea is an indication of poor
response to systemic antibiotics. Clin Exp Dermatol 1992;17:173–5.
539 Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills
for the treatment of acne. Cochrane Database Syst Rev 2012;(7):CD004425.
540 Greenwood R, Brummitt L, Burne B, et al. Acne: double‐blind clinical and laboratory trial of tetracycline, oestrogen, cyproterone acetate and combined treatment. BMJ 1985;291:1231–5.
541 Vasilakis‐Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone contraceptives. Lancet 2001;358:1427–9.
542 Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol
2004;22:419–28.
543 Farquhar C, Lee O, Toomath R, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev
2003;(4):CD000194.
544 Greenwood R, Jones DH, Brummitt L. Comparison of isotretinoin and cyproterone acetate: a clinical and laboratory study. In: Cunliffe WJ, Miller AJ, eds.
Retinoid Therapy. Lancaster: MTP Press, 1984:287–92.
545 Larsen TH, Jemec GB. Acne: comparing hormonal approaches to antibiotics
and isotretinoin. Exp Opin Pharmacother 2003;4:1097–103.
546 Gollnick HP, Graupe K, Zaumseil RP. Cmparison of combined azelaic acid
cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol
2001;11:538–44.
547 Oprica C, Emtesam L, Hagstromer L, et al. Clinical and microbiological comparisons of isotretinoin vs tetracycline in acne vulgaris. Acta Derm Venereol
2007;87:246–54.
548 Agarwal US, Besarwal RK, Bhola K. Oral isotretinoin in different dose regimens
for acne vularis: a randomized comparative trial. Indian J Dermatol Venereol Leprol 2011;77:688–94.
549 Lee JW, Yoo KH, Park KY, et al. Effectiveness of conventional, low dose and
intermittent oral isotretinoin in the treatment of acne: a randomized, controlled
comparative study. Br J Dermatol 2011;164:1369–75.
550 Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European
Directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006;20:773–6.
551 European Directive for systemic isotretinoin prescription. European Agency
for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP) http://www.ema.europa.eu/docs/en_GB/document_
library/Referrals_document/Isotretinoin_29/WC500010882.pdf (last accessed
November 2015).
552 Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology
2002;204:232–5.
553 Amichai B, Grunwald MH. Isotretinoin in dermatology. J Dermatol Treat
2000;11:219–40.
554 Zane LT, Leyden WA, Marqueling AL, et al. A population based analysis of
laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch
Dermatol 2006;142:1016–22.
555 Strauss JA, Rapini RP, Shalita AR, et al. Isotretinoin therapy for acne: results of
a multicentre dose–response study. J Am Acad Dermatol 1994;10:490–6.
556 Shalita AR. Acne revisited. Arch Dermatol 1994;130:363–4.
557 Layton AM, Knaggs H, Taylor J, et al. Isotretinoin for acne vulgaris – 10 years
later: a safe and successful treatment. Br J Dermatol 1993;129:292–6.
558 Cunliffe WJ, van de Kerkhof P, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997;194;351–7.
559 Gollnick H, Cunliffe WJ, Berson D, et al. Management of acne. A report from a
Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49(1
Suppl.):S1–36.
560 Eady EA, Jones CE, Tipper JL, et al. Antibiotic resistant propionibacteria in acne:
need for policies to modify usage. BMJ 1993;306:555–6.
561 Harms M, Masooye I, Radeff B. The relapses of cystic acne after isotretinoin treatment are age‐related: a long‐term follow up study. Dermatologica
1986;172:148–53.
562 Goulden V, Clark SM, McGeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997;137:106–8.
11 March 2016 7:24 PM
References
563 Akman A, Durusoy C, Senturk M, et al. Treatment of acne with intermittent and
conventional isotretinoin: a randomized, controlled multicenter study. Arch
Dermatol Res 2007;299:467–73.
564 Goulden V, Clark SM, Cunliffe WJ. Treatment of adult acne with low dose intermittent isotretinoin. Br J Dermatol 1996;135(Suppl. 47):20.
565 Horne HL, Carmichael AJ. Juvenile nodulocystic acne responding to systemic
isotretinoin. Br J Dermatol 1997;136:796–7.
566 Miller IM, Echeverría B, Torrelo A, Jemec GB. Infantile acne treated with oral
isotretinoin. Pediatr Dermatol 2013;3:513–18.
567 Eichenfield LF, Krakowski AC, Piggot C, et al. Evidence based recommendations
for the diagnosis and treatment of pediatric acne. Pediatrics 2013;131(Suppl.
3):S163–86.
568 Clark SM, Cunliffe WJ. The use of isotretinoin in the treatment of acne in children. Br J Dermatol 1995;133(Suppl. 45):39.
569 Parker TL, Roth JG, Esterly NB. Isotretinoin for acne in Apert syndrome. Pediatr
Dermatol 1992;9:298–300.
570 Williams REA, Doherty VR, Perkins W, et al. Staphylococcus aureus and
intra‐nasal mupirocin in patients receiving isotretinoin for acne. Br J Dermatol
1992;126:362–6.
571 Stern RS. When a uniquely effective drug is teratogenic: the case of isotretinoin.
N Engl J Med 1989;320:1007–9.
572 Jacobs DG, Deutsch NL, Brewer M. Suicide, depression and isotretinoin: is
there a causal link? J Am Acad Dermatol 2001;45:S168–75.
573 Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide
in patients treated with isotretinoin. J Am Acad Dermatol 2001;45:515–19.
574 Jick SS, Kremmers HM, Vasilakis‐Scaramozza C. Isotretinoin use and risk of
depression, psychotic symptoms, suicide and attempted suicide. Arch Dermatol
2000;136:1231.
575 Cohen J, Adams S, Patten S. No association found between patients receiving
isotretinoin for acne and the development of depression in a Canadian prospective cohort. Can J Clin Pharmacol 2007;14:S227–33.
576 Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients
with acne vulgaris: a case crossover study. J Clin Psychiatry 2008;69:526–32.
577 Lee AG. Pseudotumor cerebri after treatment with tetracycline and isotretinoin
for acne. Cutis 1995;55:165–8.
578 Clark SM, Cunliffe WJ. Acne flare and isotretinoin: incidence and treatment. Br
J Dermatol 1995;133(Suppl. 45):26.
579 Pepall LM, Cosgrove MP, Cunliffe WJ. Ablation of whiteheads by cautery
under topical anaesthesia. Br J Dermatol 1991;125:256–9.
580 Soria C, Allegue F, Galiana J, et al. Decreased isotretinoin efficacy during acute
alcohol intake. Dermatologica 1991;182:203.
581 Tam M, Cooper A. The use of isotretinoin in a renal transplant patient with
acne. Br J Dermatol 1988;116:463.
582 Kinaly C, Valkamo MH. Renal transplantation and isotretinoin. Acta Derm
Venereol (Stockh) 1990;70:540.
583 Verschoore M, Langner A, Wolska H, et al. Efficacy and safety of CD271 alcoholic
gels in the topical treatment of acne vulgaris. Br J Dermatol 1991;124:368–71.
584 Bernstein JE, Lorincz AL. The effects of topical nicotinamide, tetracycline
and dapsone and potassium iodide‐induced inflammation. J Invest Dermatol
1988;74:257–8.
585 Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne
vulgaris. J Dermatol Treat 1995;6(Suppl. 1):8–10.
586 Shalita AR, Smith JG, Parish LC, et al. A double‐blind comparison of topical
nicotinamide with clindamycin gel for the treatment of inflammatory acne vulgaris. Int J Dermatol 1995;34:34–7.
587 Shalita AR. Treatment of mild and moderate acne vulgaris with salicyclic acid
in an alcohol‐detergent vehicle. Cutis 1981;28:556–8.
588 Eady EA, Burke BM, Pulling K, et al. The benefit of 2% salicylic acid lotion in
acne: a placebo controlled study. J Dermatol Treat 1996;7:93–6.
589 Mills OH, Kligman AM. Is sulphur helpful or harmful in acne vulgaris? Br J
Dermatol 1972;86:620–7.
590 Strauss JS, Goldman PH, Nacht S, et al. A re‐examination of the potential comedogenicity of sulfur. Arch Dermatol 1978;114:1340–2.
591 Mills OH, Kligman AM. Assay of comedolytic activity in acne patients. Acta
Derm Venereol (Stockh) 1983;63:68–71.
592 MacDonald‐Hull SM, Cunliffe WJ. The use of a corticosteroid cream for immediate reduction in the clinical signs of acne vulgaris. Acta Derm Venereol (Stockh)
1989;69:452–3.
c90_ref.indd 11
90.11
593 Higaki S, Nakamura M, Morohashi M, et al. Anti‐lipase activity of Kamkpo formulations, coptidis rhizoma and its alkaloids against Propionibacterium acnes.
J Dermatol 1996;23:310–14.
594 Ernst E, Huntley A. Tea tree oil: a systematic review of randomised trials. Forsch
Komplementarmed Klass Naturheikd 2000;7:17–20.
595 Magin PJ, Adams J, Pond CD, et al. Topical and oral CAM in acne: a review of
the empirical evidence and consideration of its context. Complement Ther Med
2006;14:62–76.
596 Bagherani N, Smoller B. Role of tea tree oil in treatment of acne. Dermatol Ther
2015 doi: 10.1111/dth.12235.
597 Pepall LM, Cosgrove MP, Cunliffe WJ. Ablation of whiteheads by cautery
under topical anaesthesia. Br J Dermatol 1991;125:256–9.
598 Yip J, Peppall L, Gawkrodger DJ, Cunliffe WJ. Light cautery and EMLA® in the
treatment of chloracne lesions. Br J Dermatol 1993;128:313–16.
599 Bottomley WW, Yip J, Knaggs H, Cunliffe WJ. Treatment of closed comedones:
comparisons of fulguration with topical tretinoin and electrocautery with fulguration. Dermatology 1993;186:253–7.
600 Elman M, Slatkine M, Harth Y. The effective treatment of acne vulgaris by
a high‐intensity, narrow band 405–420 nm light source. J Cosmet Laser Ther
2003;5:111–17.
601 Tzung TY, Wu KH, Huang ML. Blue light phototherapy in the treatment of
acne. Photodermatol Photoimmunol Photomed 2004;20:266–9.
602 Zhong JQ, Xian DH, Chen DY. The clinical efficacy of narrowband blue light in
the treatment of acne vulgaris. J Clin Dermatol 2007;36:115–16.
603 Hongcharu W, Taylor CR, Chang Y, et al. Topical ALA‐photodynamic therapy
for the treatment of acne vulgaris. J Invest Dermatol 2000;115:183–92.
604 Zeina B, Greenman J, Corry D, et al. Cytotoxic effects of antimicrobial photodynamic therapy on keratinocytes. Br J Dermatol 2002;146:568–73.
605 Hædersdal M, Togsverd‐Bo K, Wulf HC. Evidence‐based review of lasers, light
sources and photodynamic therapy in the treatment of acne vulgaris. J Eur Acad
Dermatol Venereol 2008;22:267–78.
606 Orringer JS, Kang S, Maier L, et al. A randomized, controlled, split‐face clinical
trial of 1320–nm Nd:YAG laser therapy in the treatment of acne vulgaris. J Am
Acad Dermatol 2007;56:432–8.
607 Chang SE, Ahn SJ, Rhee DY, et al. Treatment of facial acne papules and pustules
in Korean patients using an intense pulsed light device equipped with a 530‐ to
750‐nm filter. Dermatol Surg 2007;33:676–9.
608 Yeung CK, Shek SY, Bjerring P, et al. A comparative study of intense pulsed
light alone and its combination with photodynamic therapy for the treatment
of facial acne in Asian skin. Lasers Surg Med 2007;39:1–6.
609 Seaton E, Charikida A, Mouser PE, et al. Pulsed dye laser treatment for inflammatory acne vulgaris: a randomised controlled trial. Lancet 2003;362:1347–52.
610 Alexiades‐Armenakas M. Long‐pulsed dye laser‐mediated photodynamic
therapy combined with topical therapy for mild to severe comedonal, inflammatory or cystic acne. J Drugs Dermatol 2006;5:45–55.
611 Yeung CK, Shek SY, Bjerring P, et al. A comparative study of intense pulsed
light alone and its combination with photodynamic therapy for the treatment
of facial acne in Asian skin. Lasers Surg Med 2007;39:1–6.
612 Furukawa F, Yamamoto Y. Recent advances in chemical peeling in Japan. J Dermatol 2006;33:655–61.
613 Dreno B, Fischer TC, Perosino E, et al. Expert opinion: efficacy of superficial
chemical peels in active acne management: what can we learn from the literature today? Evidence based recommendations. J Eur Acad Dermatol Venereol
2011;25:695–704.
614 Burns RE, Colville JM. Acne conglobata with septicaemia. Arch Dermatol
1959;79:361–3.
615 Plewig G, Kligman AM. Acne: Morphogenesis and Treatment. Berlin: Springer‐
Verlag, 1975:196.
616 Karoven SL. Acne fulminans: report of clinical findings and treatment of
twenty‐four patients. J Am Acad Dermatol 1993;28:572–9.
617 Thompson KF, Cunliffe WJ. Acne fulminans ’sine fulminans’. Clin Exp Dermatol
2000;25:299–301.
618 Zaba R, Shwatrz RA, Jarmuda S, et al. Acne fulminans: explosive systemic form
of acne. J Eur Acad Dermatol Venereol 2011;25:501–7.
619 Neely GM, Hein MS. Acne fulminans: a case report. South Dakota Med
2006;59:387–9.
620 Tamaki C, Miyatake J, Yamagat T, et al. Case of acne fulminans associated with
hemophagocytosis. Nippon Naika Zasshi 2004;93:1632–3.
11 March 2016 7:24 PM
90.12
Chapter 90: Acne
621 Kurokawa S, Tokura Y, Nham NS, et al. Acne fulminans coexisting with
pyoderma gangrenosum‐like eruptions and posterior scleritis. J Dermatol
1996;23:37–41.
622 McAuley D, Miller RA. Acne fulminans associated with inflammatory bowel
disease: report of a case. Arch Dermatol 1985;121:91–3.
623 Wakabayashi M, Fujimoto N, Uenishi T, Danno K, Tanaka T. A case of acne
fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans,
rosacea fulminans and neutrophilic dermatoses occurring in the setting of
inflammatory bowel disease. Dermatology 2011;222:231–5.
624 Kurokawa S, Tokura Y, Nham NX, et al. Acne fulminans coexisting with
pyoderma gangrenosum‐like eruptions and posterior scleritis. J Dermatol
1996;23:37–41.
625 Tallon B, Corkill M. Peculiarities of PAPA syndrome. Rheumatology 2006;45:1140–3.
626 Fyrand O, Fiskadaal HJ, Trygstad O. Acne in pubertal boys undergoing treatment with androgens. Acta Derm Venereol (Stockh) 1992;72:148–9.
627 Traupe H, von Muhendahl KE, Bramswig J, et al. Acne of the fulminans type
following testosterone therapy in three excessively tall boys. Arch Dermatol
1988;124:414–17.
628 Hartmann AA, Burg G. Acne fulminans bei Klinefelter‐Syndrom unter Testosteron. Monatsschr Kinderheilkd 1989;137:466–7.
629 McFadden N. Testosterone‐induced acne fulminans in a patient treated for tall
stature. J Dermatol Treat 1989;1:33–4.
630 Wollina U, Hansel G, Koch A, et al. Case reports: acne fulminans in Marfan’s
syndrome. J Drugs Dermatol 2005;4:501–5.
631 Placzek M, Degitz K, Schmidt H, Plewig G. Acne fulminans in late‐onset congenital adrenal hyperplasia. Lancet 1999;354:739–40.
632 Heydenreich G. Testosterone and anabolic steroids and acne fulminans. Arch
Dermatol 1989;125:571–2.
633 Krauss SL, Emmert S, Schon M, et al. The dark side of beauty: acne fulminans induced by anabolic steroids in a male body builder. Arch Dermatol
2012;148:1210–11.
634 Melnik B, Jansen T, Grabbe S. Abuse of anabolic‐androgenic steroids and
bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges
2007;5:110–17.
635 Scott MJ III, Scott AM. Effects of anabolic‐androgenic steroids on the pilosebaceous unit. Cutis 1992;50:113–16.
636 Kellet JK, Beck MH, Chalmers RJG. Erythema nodosum and circulating
immune complexes in acne fulminans after treatment with isotretinoin. BMJ
1985;290:820.
637 Karvonen SL, Rasanen L, Cunliffe WJ, et al. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans.
Dermatology 1994;189:344–9.
638 Perkins W, Crocket KV, Hodgkins MB, et al. The effect of 13‐cis‐retinoic acid on
the metabolic burst of peripheral blood neutrophils from patients with acne. Br
J Dermatol 1991;124:429–32.
639 Darley CR, Currey HL, Baker H. Acne fulminans with arthritis in identical
twins treated with isotretinoin. J R Soc Med 1984;77:328–30,
640 Gonzales T, Gantes M, Bustabad S, et al. Acne fulminans associated with arthritis in monozygotic twins. J Rheumatol 1985;12:389–90.
641 Wong SS, Pitchard MH, Holt PJA. Familial acne fulminans. Clin Exp Dermatol
1992;17:351–3.
642 Homna M, Murakami M, Iinuma S, et al. Acne fulminans following a measles
infection. J Dermatol 2009;36:471–3.
643 Jansen T, Romiti R, Woitalla S, et al. Eruptive acne vulgaris with infectious mononucleosis. Br J Dermatol 2000;142:837–8.
644 Mehrany K, Kist JM, Weenig RH, et al. Acne fulminans. Int J Dermatol
2005;44:132–3.
645 van Schaardenburg D, Lavrijsen S, Vermeer B‐J. Acne fulminans associated
with painful splenomegaly. Arch Dermatol 1989;125:132–3.
646 Williamson DM, Cunliffe WJ, Gatecliff M, et al. Acute ulcerative acne conglobata (acne fulminans) with erythema nodosum. Clin Exp Dermatol 1977;2:351–4.
647 Lane JM, Leyden JJ, Spiegel RJ. Acne arthralgia. J Bone Joint Surg 1976;58:673–5.
648 Siegel D, Strosberg JM, Wiese F, et al. Acne fulminans with osteolytic bone
lesions responsive to dapsone. J Rheumatol 1982;92:344–6.
649 Kellet JK, Beck MH, Chalmers RJG. Erythema nodosum and circulating
immune complexes in acne fulminans after treatment with isotretinoin. BMJ
1985;290:820.
c90_ref.indd 12
650 Laasonen LS, Karvonen SL, Reunala TL. Bone disease in adolescents with acne
fulminans and severe cystic acne: radiologic and scintigraphic findings. Am J
Roentgenol 1994;162:1161–5.
651 Siegel D, Strosberg JM, Wiese F, et al. Acne fulminans with osteolytic bone
lesions responsive to dapsone. J Rheumatol 1982;92:344–6.
652 Chua SL, Ravenscroft J. Acne fulminans: part of a spectrum of SAPHO. Br J
Dermatol 2007;156:1408.
653 Chua SL, Angus JE, Ravenscroft J, et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome and acne fulminans: are they part of the same
disease spectrum? Clin Exp Dermatol 2009;34:241–3.
654 Nault P, Lassonde M, St‐Antoine P. Acne fulminans with osteolytic lesions. Arch
Dermatol 1985;121:662–4.
655 Knuchel M, Luderschmidt CR. Knochennikrose bei acne conglobata. Z Hautkr
1986;61:1092–8.
656 Strom S, Thyresson N, Bostrom H. Acute febrile ulcerative conglobate acne
with leukemoid reaction. Acta Derm Venereol (Stockh) 1973;53:306–12.
657 Jemec GBE, Rasmussen I. Bone lesions of acne fulminans: case report and
review of the literature. J Am Acad Dermatol 1989;20:353–7.
658 Knitzer RH, Needleman BW. Musculoskeletal syndromes associated with acne.
Semin Arthritis Rheum 1991;20:247–55.
659 Choi EH, Bang D. Acne fulminans and 13‐cis‐retinoic acid. J Dermatol
1992;19:378–83.
660 Karvonen SL, Vaalasti A, Kautiainen H, Reunala T. Systemic corticosteroid and
isotretinoin treatment in cystic acne. Acta Derm Venereol (Stockh) 1993;73:452–5.
661 Jansen T, Plewig G. Acne fulminans. Int J Dermatol 1998;37:254–7.
662 Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during
isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997;22:26–7.
663 Prendiville I, Cream JJ. Clofazimine responsive acne vulgaris. Br J Dermatol
1983;109(Suppl. 24):90–1.
664 Allison MA, Dunn CL, Pearson CA. Acne fulminans treated with isotretinoin
and pulsed corticosteroid. Pediatr Dermatol 1997;4:39–42.
665 Woolfson H, Road H. Acne fulminans with circulating immune complexes and
leukemoid reaction treated with steroids and azathioprine. Clin Exp Dermatol
1987;12:463–6.
666 Tago O, Nagai Y, Matsushima Y, et al. A case of acne fulminans treated with
cyclosporine A and prednisolone. Acta Derm Venereol (Stockh) 2011;91:337–8.
667 Giaevedoni P, Mascaro‐Galy J, Aguilera P, et al. Acne fulminans successfully
treated with cyclosporine and isotretinoin. J Am Acad Dermatol 2014;70:e38–9.
668 Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25
cases. Br J Dermatol 1999;141:307–9.
669 Hartmann RR, Plewig G. Acne fulminans: tratamento de 11 pacientes com o
ácido 13‐cis‐retinóico. An Bras Dermatol 1983;58:3–10.
670 Von Den Driesch P, Schell H, Haneke E. Fulminant acne: therapy with 13‐cis‐
retinoic acid and indomethacin. Z Hautkr 1986;61:1145–51.
671 Lages R, Bona SH, Silva FV, Gomes AK, Campelo V. Acne fulminans successfully treated with prednisone and dapsone. An Bras Dermatol 2012;87:612–14.
672 Patterson WM, Stibich AS, Dobke M, Schwartz RA. Mutilating facial acne conglobata. Cutis 2000;66:139–40.
673 Pagano A, Feldman MJ. Management of chronic gluteal follicular occlusive disease. Eplasty 2013;13:ic50.
674 Chicarilli N. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata and dissecting cellulites of the scalp. Ann Plast Surg 1987;18:230–7.
675 Ehrenfeld M, Samra Y, Kaplinsky N, et al. Acne conglobata and arthritis: report
of a case and review of the literature. Clin Exp Rheumatol 1986;5:407–9.
676 Vasey FB, Fenske NA, Clement GB, et al. Immunological studies of the arthritis of acne conglobate and hidradenitis suppuritiva. Clin Exp Rheumatol
1984;2:309–11.
677 Ziff M, Maliakkal J. Acne conglobate and arthritis. Ann Intern Med 1983;98:417.
678 Lim DT, James NM, Hassan S, et al. Spondyloarthritis associated with acne
congolobata, hidradentitis suppuritiva and dissecting cellulitis of the scalp: a
review with illustrative cases. Curr Rheumatol Rep 2013;15:346.
679 Velez A, Alcala J, Fernadez‐Roldan JC. Pyoderma gangrenosum associated
with acne conglobate. Clin Exp Dermatol 1995;20:496–8.
680 Benhamou CL, Enjolras O, Delrieu F, et al. The SAPHO syndrome. Semin Arthritis Rheum 2012;42:254–6.
681 Braun‐Falco M, Kovverystyy O, Lohse P, et al. Pyoderma gangrenosum, acne
and suppurative hidradrenitis suppuritiva (PASH): a new autoinflammatory
syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012;66:409–15.
11 March 2016 7:24 PM
References
682 Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis and axial sponyloarthritis: efficacy of anti‐tumor necrosis factor a therapy. J
Clin Rheumatol 2012;18:413–15.
683 Melnik B, Jansen T, Grabbe S. Abuse of anabolic‐androgenic steroids and
body building acne: an underestimated health problem. J Dtsch Dermatol Ges
2007;5:110–17.
684 Ena P, Zanetti S, Sechi LA. Mycobacertium chelonae I infection mimicking acne
conglobate in an immunocompetent host. Clin Exp Dermatol 2004;29:423–5.
685 Yeon HB, Lindon NM, Seidman JG, et al. Pyogenic arthritis, pyoderma gangrenosum and acne syndrome maps to chromosome 15q. Am J Hum Genet
2000;66:1443–8.
686 Wollenberg A, Wolff H, Jansen T, et al. Acne conglobate and Klinefelter’s syndrome. Br J Dermatol 1997;136:421–3.
687 Schackert K, Scholz S, Steinbauer‐Rosenthal I, et al. HLA‐A antigens in acne
conglobate: a negative study. Arch Dermatol 1974;110:468.
688 Whipp MJ, Harrington CI, Dundas S. Fatal squamous cell carcinoma associated
with acne conglobata in a father and daughter. Br J Dermatol 1987;117:389–92.
689 Birnkrant MJ, Papdopoulos AJ, Scwartz RA, et al. Pyoderma gangrenosum,
acne conglobate and IgA gammopathy. Int J Dermatol 2003;42:213–16.
690 Perez‐Villa F, Campistol JM, Ferrando J, et al. Renal amyloidosis secondary to
acne conglabata. Int J Dermatol 1989;28:132–3.
691 Leyden JJ, Mills OH, Kligman AM. Cryoprobe treatment of acne conglabata. Br
J Dermatol 1974;90:335–41.
692 Weinrack L, Peled I, Hacham‐Zadah S, et al. Surgical treatment of severe acne
conglobate. J Dermatol Surg Oncol 1981;7:492–4.
693 Haregawa T. Acne conglobate successfully treated by fractional laser after
CO2 laser abrasion of cysts combined with topical tretinoin. J Dermatol
2009;36:118–19.
694 Myers JN, Mason AR, Gillespie LK, et al. Treatment of acne conglobate with
modern external beam radiation. J Am Acad Dermatol 2010;62:861–3.
695 Jeong SJ, Lee CW. Acne conglobata: treatment with isotretinoin, colchicine
and cyclosporin as compared with surgical intervention. Clin Exp Dermatol
1996;21:462–3.
696 Schwartz RA. Acne conglobata treatment and management http://emedicine.
medscape.com/article/1072716‐treatment (last accessed November 2015).
697 Bolz S, Jappe U, Hartschuh W. Successful treatment of peri‐folliculitis capitis
abscendens et suggodiens with combined isotretinoin and dapsone. J Dtsch
Dermatol Ges 2008;6:44–7.
698 Shirakam M, Uramoto K, Harad FA, et al. Treatment of acne conglobata with
infiliximab. J Am Acad Dermatol 2006;55:344–6.
699 Schuttelaar ML, Leeman FW. Sustained remission of nodular inflammatory
acne after treatment with infliximab. Clin Exp Dermatol 2011;36:670–1.
700 Campione E, Mazzotta AM, Bianchi L, et al. Severe acne successfully treated
with etanercept. Acta Derm Venereol (Stockh) 2006;86:256–7.
701 Su YS, Chang CH. SAPHO syndrome associated with acne conglobata successfully treated with etancercept. J Formos Med Assoc 2015;114:562–4.
702 Sand F. Adalimumab for the treatment of refractory acne conglobata. JAMA
Dermatol 2013;149:1307.
703 Yang GL, Zhao M, Wang JM, et al. Short‐term clinical effects of photodynamic therapy with topical 5‐aminolevulinic acid for facial acne conglobate:
an open prospective, parallel arm trial. Photodermatol Photoimmunol Photomed
2013;29:233–8.
704 Jeong SJ, Lee CW. Acne conglobata: treatment with isotretinoin, colchicine
and cyclosporin as compared with surgical intervention. Clin Exp Dermatol
1996;21:462–3.
705 Schwartz RA. Acne conglobata treatment and management, 2012 http://
emedicine.medscape.com/article/1072716‐treatment (last accessed November
2015).
706 Haregawa T, Matsukura T, Suga Y. One case of acne conglobata treated by the
CO2 laser combined with tretinoin. J Dermatol 2007;34:583–5.
707 Bolz S, Jappe U, Hartschuh W. Successful treatment of perifolliculitis capitis
abscendens et suggodiens with combined isotretinoin and dapsone. J Dtsch
Dermatol Ges 2008;6:44–7.
708 Yung‐Shun Su, Chung‐Hsing Chang, SAPHO syndrome associated with
acne conglobate successfully treated with etancercept. J Formosan Med Soc
2013;xx:1–3.
709 Jansen T, Linder A, Plewig G. Draining sinus in acne and rosacea. A clinical,
histopathologic and experimental study. Hautarzt 1995;46:417–20.
c90_ref.indd 13
90.13
710 Herxheimer K. Über Chloracne. Münch Med Wochenschr 1899;46:278.
711 Zouboulis CC. Acne venenata und acne cosmetica. In: Braun‐Falco O, Gloor
M, Korting HC, eds. Nutzen und Risiko von Kosmetika. Berlin: Springer‐Verlag,
2000:116–23.
712 Ju Q, Yiang K, Zouboulis CC, Ring J, Chen W. Chloracne: from clinic to research.
Dermatol Sinica 2012;30:2–6.
713 Ju Q, Zouboulis CC, Xia L. Environmental pollution and acne‐chloracne. Dermatoendocrinology 2009;1:125–8.
714 McDonnell JK, Taylor JS. Occupational and environmental acne. In: Kanerva L,
Elsner P, Wahlberg JE, Maibach HI, eds. Handbook of Occupational Dermatology.
Berlin: Springer‐Verlag, 2000:225–33.
715 Ju Q, Zouboulis CC. Effects of 2,3,7,8‐tetrachlorodibenzo‐p‐dioxin on the skin.
Biosafety 2013;2:3.
716 Kimmig J, Schulz KH. Berufliche Akne (sog. Chlorakne) durch chlorierte aromatische zyklische Äther. Dermatologica 1957;115:540–6.
717 Zober A, Messerer P, Huber P. Thirty‐four‐year mortality follow‐up of BASF
employees exposed to 2,3,7,8‐TCDD after the 1953 accident. Int Arch Occup
Environ Health 1990;62:139–57.
718 Dalderup LM, Zellenrath D. Dioxin exposure: 20 year follow‐up. Lancet
1983;ii:1134–5.
719 Pesatori AC, Consonni D, Bachetti S, et al. Short‐ and long‐term morbidity and
mortality in the population exposed to dioxin after the ’Seveso accident’. Ind
Health 2003;41:127–38.
720 Yoshimura T. Yusho in Japan. Ind Health 2003;41:139–48.
721 Lü YC, Wu YC. Clinical findings and immunological abnormalities in Yu‐
Cheng patients. Environ Health Perspect 1985;59:17–29.
722 Institute of Medicine (US) Committee to Review the Health Effects in Vietnam
Veterans of Exposure to Herbicides. Veterans and Agent Orange: Update 2000
(Third Biennial Update). Washington, DC: National Academies Press, 2001.
723 Saurat JH, Kaya G, Saxer‐Sekulic N, et al. The cutaneous lesions of dioxin
exposure: lessons from the poisoning of Victor Yushchenko. Toxicol Sci
2012;125:310–17.
724 Geusau A, Abraham K, Geissler K, Sator MO, Stingl G, Tschachler E. Severe
2,3,7,8‐tetrachlorodibenzo‐p‐dioxin (TCDD) intoxication: clinical and laboratory effects. Environ Health Perspect 2001;109:865–9.
725 Geusau A, Tschachler E, Meixner M, et al. Olestra increases faecal excretion of
2,3,7,8‐tetrachlorodibenzo‐p‐dioxin. Lancet 1999;354:1266–7.
726 Kim W, Mancinic AJ. Acne in childhood: an update. Pediatr Ann 2013;42:418–27.
727 Bernier V, Weill FX, Hirigoyen V, et al. Skin colonization with Malassezia species in neonates: a prospective study and relationship with neonatal cephalic
pustulosis. Arch Dermatol 2002;138:215–18.
728 Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology
2003;206:24–8.
729 Katsambas AD, Katoulis AC, Stavropoulos P. Acne neonatorum: a study of 22
cases. Int J Dermatol 1999;38:128–30.
730 Yonkosky DM, Pochi PE. Acne vulgaris in childhood: pathogenesis and management. Dermatol Clin 1986;4:127–36.
731 Mancini AJ, Baldwin HE, Eichenfield LF, et al. Acne life cycle: the spectrum of
pediatric disease. Semin Cutan Surg 2011;30(3 Suppl.):S2–5.
732 Mancini AJ, Baldwin HE, Eichenfield LF. Acne life cycle: the spectrum of pediatric disease. Semin Cutan Med Surg 2011;30(3 Suppl.):S2–S5.
733 Antoniou C, Dessinioti C, Stratigos AJ, et al. Clinical and therapeutic approach
to childhood acne: an update. Pediatr Dermatol 2009;26:373–80.
734 Hello M, Perry S, Leaute‐Labreze C, et al. Infantile acne: a retrospective study of
16 cases. Pediatr Dermatol 2008;25:434–8.
735 Biro FM, Huang B, Crawford PB, et al. Pubertal correlates in black and white
girls. J Pediatr 2006;148:234–40.
736 Benedetta C, Beretta‐Piccoli MJ, Sauvain IM, et al. Synovitis, acne, pustulosis,
hyperostosis and osteitis (SAPHO) syndrome in childhood: a report of ten cases
and review of the literature. Eur J Pediatr 2000;159:595–601.
737 Brazzelli V, Larizza D, Muzio F, et al. Low frequency of acne vulgaris in adolescent girls and women with Turner’s syndrome: a clinical, genetic and hormonal
study of 65 patients. Br J Dermatol 2008;159:1209–11.
738 Lucky AW. A review of infantile and paediatric acne. Dermatology 1998;196:95–7.
739 Chew EW, Bingham A, Burrows D. Incidence of acne vulgaris in patients with
infantile acne. Clin Exp Dermatol 1990;15:376–7.
740 Stewart ME, Downing DT, Cook JS, et al. Sebaceous gland activity and serum
dehydroepiandrosterone sulfate levels in boys and girls. Arch Dermatol
1992;128:1345–8.
11 March 2016 7:24 PM
90.14
Chapter 90: Acne
741 Lucky A, Biro FM, Simbart LA, et al. Predictors of severity of acne vulgaris
in young adolescent girls: results of a five‐year longitudinal study. J Pediatr
1997:130:30–9.
742 Mann MW, Ellis SS, Mallory SB. Infantile acne as the initial sign of an adrenocortical tumor. J Am Acad Dermatol 2007;56(2 Suppl.):S15–18.
743 Schroeder B. Early diagnosis, presenting complaints and management of
hyperandrogenism in adolescents. Curr Womens Health Rep 2001;1:124–30.
744 Degitz K, Placzek M, Arnold B, et al. Congenital adrenal hyperplasia and acne
in male patients. Br J Dermatol 2003;146:1263–6.
745 Mourelatas K, Eady EA, Cunliffe WJ, et al. Temporal changes in sebum excretion and propionibacteria: colonization in preadolescent children with and
without acne. Br J Dermatol 2007;156:22–31.
746 Rapelanoro R, Mortureux P, Couprie B, et al. Neonatal Malasezzia fufur pustulosis. Arch Dermatol 1996:132:190–3.
747 Ayhan M, Sancak B, Karaduman A, et al. Colonisation of neonatal skin by
Malasezzia species: relationship with neonatal cephalic pustulosis. J Am Acad
Dermatol 2007;57:1012–18.
748 Stankler L, Campbell AGM. Neonatal acne vulgaris: a possible feature of the
fetal hydantoin syndrome. Br J Dermatol 1980;103:453–5.
749 Nanda S, Reddy BSN, Ramji S, et al. Analytical study of pustular eruptions in
neonates. Pediatr Dermatol 2002;19:201–15.
750 Barnes CJ, Eichenfield LF, Lee J, et al. A practical approach for the use of isotretinoin for infantile acne. Pediatr Dermatol 2005;22:166–9.
751 Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29
patients with infantile acne. Br J Dermatol 2001;145:463–6.
752 Cantatore‐Francis JL, Glick SA. Childhood acne: evaluation and management.
Dermatol Ther 2006;19:202–9.
753 Saenger P, Dimartino‐Nardi J. Premature adrenarche. J Endocrinol Invest
2001;24:724–33.
754 Idkowiak J, Lavery GG, Dhir V, et al. Premature adrenarche: novel lessons from
early onset androgen excess. Eur J Endocrinol 2011;165:189–201.
755 Aracting S, Cadranel S, Reygagne P, et al. Pustulose neonatale induite par
Malasezzia furfur. Ann Dermatol Vénéréol 1991;118:856–8.
756 Bergman JN, Eichenfield LF. Neonatal acne and cephalic pustulosis: is Malassezia the whole story? Arch Dermatol 2002;138:255–7.
757 Niamba P, Weill FX, Sarlangue J, et al. Is common neonatal cephalic pustulosis (neonatal acne) triggered by Malassezia synpodialis? Arch Dermatol
1998;134:995–8.
758 Bree A, Siegfried E. Acne vulgaris in preadolescent children: recommendations
for evaluation. Pediatr Dermatol 2014;31:27–32.
759 Hellier FF. Acneiform eruptions in infancy. Br J Dermatol 1954;66:25–9.
c90_ref.indd 14
760 Chew EW, Bingham A, Burrows D. Incidence of acne vulgaris in patients with
infantile acne. Clin Exp Dermatol 1990;15:376–7.
761 Dupont C. A study of juvenile acne [Letter]. Clin Exp Dermatol 1989;14:175–6.
762 Sarazin F, Dompmartin A, Nivot S, et al. Treatment of an infantile acne with oral
isotretinoin. Eur J Dermatol 2004;14:71–2.
763 Torrelo A, Pastor A, Zambrano A. Severe acne infantum successfully treated
with isotretinoin. Pediatr Dermatol 2005;22:357–9.
764 Brechler AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in
children and adolescents. J Am Acad Dermatol 2003;49:171–82
765 Burkett JM, Storrs FJ. Nodulocystic infantile acne occurring in a kindred of steatocystoma. Arch Dermatol 1987;123:432–3.
766 Arbegast KD, Braddock SW, Lamberty FL, et al. Treatment of infantile cystic
acne with oral isotretinoin. Pediatr Dermatol 1991;8:166–8.
767 Horne HL, Carmichael AJ. Juvenile nodulocystic acne responding to systemic
isotretinoin. Br J Dermatol 1997:136:796–7.
768 Leaute‐Labreze C, Gautier C, Labbe L, et al. Infantile acne and isotretinoin. Ann
Dermatol Venereol 1998:125:132–4.
769 Mengesha YM, Hansen RC. Toddler‐age nodulocystic acne. J Pediatr
1999;134:644–8.
770 Cunliffe WJ, Baron SE, Coulson IH. A clinical and therapeutic study of 29
patients with infantile acne. Br J Dermatol 2001;145:463–6.
771 Sarazin F, Dompmartin A, Nivot S, et al. Treatment of an infantile acne with oral
isotretinoin. Eur J Dermatol 2004;14:71–2.
772 Barnes CJ, Eichenfield LF, Lee J, et al. A practical approach for the use of oral
isotretinoin for infantile acne. Pediatr Dermatol 2005;22:166–9.
773 Hello M, Prey S, Leaute‐Labreze C, et al. Infantile acne: a retrospective study of
16 cases. Pediatr Dermatol 2008;25:434–8.
774 Miller IM et al. Infantile acne treated with oral isotretinoin. Pediatr Dermatol
2013;3:513–18.
775 Holm EA, Jemec GB. Acne neonatorum/acne infantum. Ugeskr Laeger
2000;162:68567.
776 Torello A, Pastor MA, Zambrano A. Severe acne infantum successfully treated
with isotretinoin. Pediatr Dermatol 2005;22:3579.
777 Lee SE, Kim J‐M, Jeong SK, Choi EH, Zouboulis CC, Lee SH. Expression of
protease‐activated receptor‐2 in SZ95 sebocytes and its role in sebaceous lipogenesis, inflammation, and innate immunity. J Invest Dermatol 2015;135:2338.
778 Huang YC, Yang CH, Li TT, Zouboulis CC, Hsu HC. Cell‐free extracts of Propionibacterium acnes stimulate cytokine production through activation of p38
MAPK and Toll‐like receptor in SZ95 sebocytes. Life Sci 2015;139:123–31.
11 March 2016 7:24 PM